Q2 2024 ProPhase Labs Inc Earnings Call

Wella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.

Unknown Executive: On behalf of our team, we want to thank everyone for joining us today for the Prophase Lab's second quarter of 2024 results. Prophase is trading on the NASDAQ under the ticker symbol PRPH.

Unknown Executive: On behalf of our team, we want to thank everyone for joining us today. The Prophase Labs second quarter 2024 results.

Speaker Change: On behalf of our team, we want to thank everyone for joining us today.

Unknown Executive: On behalf of our team, we want to thank everyone for joining us today for the Prophase Lab's second quarter of 2024 results. Prophase is trading on the NASDAQs under the ticker symbol PRPH.

Ted Karkus: Prophase is trading on the NASDAQ under the ticker symbol PRPH. Presenting today is Ted Karkus, Chief Executive Officer and Chairman. Following the presentation is a Q&A session for which you can participate using the chat box in the top right-hand corner of your screen. With that being said, I'll now hand the floor over to Ted. Thank you all. I really appreciate everybody joining us today for the Prophase Labs presentation. Presentation. This is our second quarter earnings release and review for our shareholders.

Ted Karkus: Prophase Lab's second quarter 2024 results. Prophase is trading on the NASDAQ under the ticker symbol PRPH. Presenting today is Ted Karkus, Chief Executive Officer and Chairman.

Unknown Executive: Presenting today is Ted Karkus, Chief Executive Officer and Chairman. Following the presentation, there is a Q&A session for which you can participate using the chat box in the top right-hand corner of your screen. With that being said, I'll now hand over to Ted.

Unknown Executive: Presenting today is Ted Karkus, Chief Executive Officer and Chairman. Following the presentation is a Q&A session for which you can participate using the chat box in the top right hand corner of your screen. With that being said, I'll now hand over to Ted. Thank you all. I really appreciate everybody joining today for the Prophase Labs presentation presentation. This is our second quarter earnings release and review for shareholders. Of course, I always have to start with forward-looking statement, except for the historical information contained here in this document contains forward-looking statements within the meeting of the private securities litigation reform act of 1995, including statements regarding our strategy plans, objectives and initiatives, including our plans to grow in our subsidiaries and build a multi-billion dollar business.

Ted Karkus: Following the presentation is a Q&A session for which you can participate using the chat box in the top right-hand corner of your screen. With that being said, I'll now hand the floor over to Ted.

Ted Karkus: Thank you all. I really appreciate everybody joining today for the Prophase Labs presentation presentation. This is our second quarter earnings release and review for shareholders.

Ted Karkus: Thank you all. I really appreciate everybody joining today for the Prophase Lab's presentation. Presentation, that is our second quarter earnings.

Ted Karkus: Of course, I always have to start with a forward-looking statement. Except for the historical information contained here in this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy plans, objectives, and initiatives, including our plans to grow in our subsidiaries and build a multi-billion-dollar business, our expected timeline for commercializing our B-SMART test, and its market potential, our belief in Project ZENQAI's potential to contribute to the identification of novel actionable targets for cancer therapies.

Ted Karkus: Of course, I always have to start with a forward-looking statement, except for the historical information contained here in this document. It contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives, and initiatives, including our plans to grow in our subsidiaries and build a multi-billion dollar business. Our expect timeline for commercializing our B Smart Test as a market potential or a belief in project ZenQAI's potential to contribute to the identification of novel, novel actionable targets for cancer therapies. Management believes that these forward-looking statements are reasonable as and when may.

Speaker Change: release and review for our shareholders.

Speaker Change: Of course, I always have to start with a forward-looking statement.

Unknown Executive: Our expect timeline for commercializing our B Smart Test as a market potential or a belief in project ZenQAI's potential to contribute to the identification of novel, novel actionable targets for cancer therapies. Management believes that these forward-looking statements are reasonable as and when may. However, such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include that are not limited to our ability to obtain and maintain necessary regulatory approval.

Ted Karkus: Except for the historical information contained herein, this document contains four looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives, and initiatives, including our plans to grow in our subsidiaries and build a multi-billion dollar business.

Ted Karkus: I'll expect timeline for commercializing our be smart test as market potential our belief in project. Thank you AI's potential to

Ted Karkus: Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.

Ted Karkus: contribute to the identification of novel actionable targets for cancer therapies.

Ted Karkus: However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include that are not limited to our ability to obtain and maintain necessary regulatory approval. General economic condition, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our annual reports on Form 10-K, quarterly reports on Form 10-Q, and any other SEC filings. The company undertakes no obligation to update forward-looking statements except as required by applicable securities laws.

Speaker Change: Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks.

Speaker Change: uncertainties and other factors that may cause actual results to differ materially from those projected in the forward-looking statements.

Ted Karkus: These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our annual reports on Form 10-K, quarterly reports on Form 10-Q, and any other SEC filings. The company undertakes no obligation to update forward-looking statements except as required by applicable securities laws.

Speaker Change: These risks and uncertainties include, but are not limited to, our ability to obtain and maintain necessary regulatory approvals.

Speaker Change: General economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our annual reports on Form 10-K , quarterly reports on Form 10-Q , and any other SEC filings.

Unknown Executive: General economic condition, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment and the risk factors listed from time to time in our annual reports on form 10K, quarterly reports on form 10Q, and any other SEC filings. The company undertakes no obligation to update forward-looking statements except is required by applicable securities laws. Readers of questions that forward-looking statements do not guarantee the future performs and are questioned not to place undue reliance on any forward-looking statements.

Ted Karkus: Readers are cautioned that forward-looking statements do not guarantee future performance and are cautioned not to place undue reliance on any forward-looking statements. So with that, Noelle, I just realized next quarter when we're doing the quarterly call because I have to read all that, I'm going to have you read it and then introduce me. All right.

Speaker Change: The company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements do not guarantee the future performance and are cautioned not to place undue reliance on any forward-looking statements.

Ted Karkus: Readers of questions that forward-looking statements do not guarantee the future performs and are questioned not to place undue reliance on any forward-looking statements.

Ted Karkus: So, with that, Noel, I just realized next quarter when we're doing the quarterly call, because they have to read all of that, I'm going to have you read it and then introduce me. All right, that's the way other companies do it. With that said, I may as well highlight the fact that Renmark, who we do our monthly virtual non-deal road show calls with, is also hosting today. We'll always update in our shareholders. I like to be an open book and keep our shareholders up to date on what we're doing. So sign up with Renmark, and every month I do a call like this.

Speaker Change: So with that, Noella, I just realized next quarter when we're doing the quarterly call because I have to read all that I'm gonna have you read it and then introduce me. All right, that's that's the way other companies do it

Unknown Executive: So with that, Noel, I just realized next quarter when we're doing the quarterly call because they have to read all of that, I'm going to have you read it and then introduce me. All right, that's the way other companies do it. With that said, I may as well highlight the fact that Renmark, who we do our monthly virtual non-deal road show calls with, is also hosting today. We'll always update in our shareholders.

Ted Karkus: That's the way other companies do it. With that said, I may as well highlight the fact that Renoirk, who we do our monthly virtual non-deal road show calls with, is also hosting today. I'm always updating our shareholders. I like to be an open book and keep our shareholders up to date on what we're doing. So sign up with Renmark. And you know, every month I do a call like this.

Speaker Change: With that said, I may as well highlight the fact that Renmark, who we do our monthly virtual non-deal roadshow calls with, is also hosting today.

Speaker Change: I'm always updating our shareholders. I like to be an open book and keep our shareholders up-to-date on what we're doing. So sign up with Renmark and every month I do a call like this. And on the calls that I do with Renmark, I don't read the forward-looking statement, I just refer to it.

Unknown Executive: I like to be an open book and keep our shareholders up to date on what we're doing. So sign up with Renmark and every month I do a call like this. And on the call that I do with Renmark, I don't read the forward-looking statement, I just report to it. With that, let's get right into it. This actually relates very closely to formalize. Look, the numbers speak for themselves. I really don't want to focus on the numbers because you can look at the financial statements yourself and quite frankly the historical financials even through the second quarter this year to me are irrelevant relative to where our company is right now today and where is going this quarter and the quarter is going for it.

Ted Karkus: And on the call that I do with Renmark, I don't read the forward-looking statement; I just report to it. With that, let's get right into it. This actually relates very closely to Formalize. Look, the numbers speak for themselves.

Ted Karkus: And on the calls that I do with Renmark, I don't read the forward-looking payment; I just refer to it. With that, let's get right into it. This actually relates very closely to pharma laws. Look, the numbers speak for themselves. I really don't want to focus on the numbers, because you can look at the financial statements yourself. And quite frankly, the historical financials, even through the second quarter this year, to me, are irrelevant relative to where our company is right now and where it's going this quarter and the quarter going forward. That's the past, which has no bearing on what the president's future is.

Speaker Change: With that, let's get right into it.

Speaker Change: This actually relates very closely to pharma laws.

Ted Karkus: I really don't want to focus on the numbers because you can look at the financial statements yourself, and quite frankly, the historical financials, even through the second quarter this year, to me are irrelevant relative to where our company is right now today and where it is going this quarter and the quarter is going for it. That's the past, which has no bearing on what the president futures. I'm going to explain that right now. So let's get right into it.

Speaker Change: look the numbers speak for themselves. I really don't want to focus on the numbers because you can look at the financial statements yourself and quite frankly the historical financials even through the second quarter this year to me are irrelevant relative to where our company is right now today and where it's going this quarter and the quarter going forward.

Ted Karkus: I'm going to explain that right now. So let's get right into it. So before we start talking about what's going on, great. A farm loss. Let me explain the second quarter a little bit. Why the revenue numbers were so low. The principal reason is farm laws. I guess I've never really explained this before, but I guess because I thought it was obvious.

Speaker Change: That's the pass.

Unknown Executive: That's the past which has no bearing on what the president futures. I'm going to explain that right now. So let's get right into it. So before we start talking about what's going on greater formalize, let me explain the second quarter a little bit why the revenue numbers were so low. The principal reason is formalize. And I guess I've never really explained this before, but I guess because I thought it was obvious, formalize is an incredibly seasonal business.

Speaker Change: which has no bearing on what the present and future is. I'm going to explain that right now. So let's get right into it. So before we start talking about what's going on in Greater Farm Labs, let me explain the second quarter a little bit, why the revenue numbers were so low. The principal reason is

Ted Karkus: So before we start talking about what's going on greater formalize, let me explain the second quarter a little bit why the revenue numbers were so low. The principal reason is formalize. And I guess I've never really explained this before, but I guess because I thought it was obvious, formalize is an incredibly seasonal business. We manufacture lots of things. Services. Companies that the Lausanne's brands are typically cold Lausanne's, they're for the common cold. These Lausanne's companies, they don't want inventory all year long. Number one, it can get still; it can expire. And they don't want to pay for it six months before they need it.

Speaker Change: Farmalaz, I guess I've never really explained this before, but I guess because I thought it was obvious, Farmalaz is an incredibly seasonal business. We manufacture lozenges.

Ted Karkus: Farm laws is an incredibly seasonal business. We manufacture laws, and companies that the lozenge grants are typically cold lozenges or for the common cold. These lodging companies don't want inventory all year long. Number one, it can get stale, it can expire.

Unknown Executive: We manufacture lots of things. Services. Companies that the Lausanne's brands are typically cold Lausanne's, they're for the common cold. These Lausanne's companies, they don't want inventory all year long. Number one, it can get still, it can expire. And they don't want to pay for it six months before they need it. So understand the cold season. We're manufacturing full bore in the third and fourth quarters by the first quarter. There's a lot of little additional manufacturing by the second quarter.

Speaker Change: Companies that the license grants are typically cold licenses or for the common cold.

Speaker Change: These lodgings companies they don't Want inventory all year long number one it can get stale it can expire And they don't want to pay for it six months before they need it so understand the cold season. We're manufacturing full bore

Ted Karkus: So understand the cold season. We're manufacturing full bore in the third and fourth quarters by the first quarter. There's a lot of little additional manufacturing by the second quarter. Nobody wants manufacturing the second quarter. So even though we increase prices, we didn't have the business, and all this is really kicking in for the third quarter. Now, going forward with interesting, there's such demand for a product. We're adjusting a couple of different ways as a potential second quarter of next year. We are now attracting Lausanne's brands that are not for the common cold that are year-round brands.

Ted Karkus: And they don't want to pay for it six months before they need it. So understand the cold season; we're manufacturing full bore in the third and fourth quarters. By the first quarter, there's a little additional manufacturing by the second quarter; nobody wants to manufacture in the second, So even though we increase prices, we didn't have the business. All this is really kicking in for the third quarter.

Speaker Change: in the third and fourth quarters. By the first quarter, there's a little additional manufacturing. By the second quarter, nobody wants to manufacture in the second quarter.

Unknown Executive: Nobody wants manufacturing the second quarter. So even though we increase prices, we didn't have the business and all this is really kicking in for the third quarter. Now going forward with interesting, there's such demand for a product. We're adjusting a couple of different ways as a potential second quarter of next year. We are now attracting Lausanne's brands that are not for the common cold that are year round brand. That will, that will help our seasonality a lot.

Speaker Change: So even though we increase prices,

Ted Karkus: Now, going forward, what's interesting is that there is such demand for a product; we're adjusting a couple of different ways as it pertains to the second quarter of next year. We are now attracting brands that are not for the common cold that are year-round brands that will help our seasonality a lot. The other thing that's happening is we're expanding. Businesses that are seasonal do still give us some business. Our overall business is expanding so much that even those brands that are seasonal will still have a fair amount of business to give us for the second quarter of next year.

Speaker Change: We didn't have the business, and all this is really kicking in for the third quarter. Now, going forward, what's interesting, there's such demand for a product, we're adjusting a couple of different ways as it pertains to the second quarter of next year. We are now attracting...

Ted Karkus: That will, that will help our seasonality a lot. The other thing that's happening is we're expanding the businesses that are seasonal do still give us some business. Our overall business is expanding so much that even those brands are seasonal will still have a fair amount of business to give us for the second quarter of next year. My point being, though, when we talk about our projections for the next 12 months, and that's why actually when I put on the press releases, starting with the third quarter of this year. It's because that's really our seasonal year, and that's what's relevant.

Speaker Change: lozenge brands that are not for the common cold that are year-round brands. That will help our seasonality a lot.

Speaker Change: The other thing that's happening is we're expanding. The businesses that are seasonal do still give us some business. Our overall business is expanding so much that even those brands that are seasonal will still have a fair amount of business to give us for the second quarter of next year. My point being, though, when we talk about

Unknown Executive: The other thing that's happening is we're expanding the businesses that are seasonal do still give us some business. Our overall business is expanding so much that even those brands are seasonal will still have a fair amount of business to give us for the second quarter of next year. My point being, though, when we talk about our projections for the next 12 months, and that's why actually when I put on the press releases, starting with the third quarter of this year.

Ted Karkus: My point is, though, when we talk about our projections for the next 12 months, and that's why, actually, when I put it in the press releases, starting with the third quarter of this year, it's because that's really our seasonal year, and that was relevant, not last year. Because, for instance, in the second half of last year, we didn't have price increases, we didn't have increased capacity, we didn't have So last year, the second half really isn't relevant to what we're doing.

Speaker Change: Our projections for the next 12 months, and that's why, actually, when I put it on the press releases, starting with the third quarter of this year, it's because that's really our seasonal year, and that was relevant. Not last year.

Ted Karkus: Not last year, because for the second half of last year, we didn't have the price increases. We didn't have the increased capacity. We didn't have the automation equipment. So last year, the second half really isn't relevant to what we're doing. And as I said, first half of this year, you know, as we got into the second quarter, we weren't taking advantage of this new capacity that we had. And we weren't taking advantage of the price increase we had. And we got these two Lord's customers, but one of them didn't even start giving us business. I believe they're now just starting to give us business in the third quarter.

Unknown Executive: It's because that's really our seasonal year, and that's what's relevant. Not last year, because for the second half of last year, we didn't have the price increases. We didn't have the increased capacity. We didn't have the automation equipment. So last year, second half really isn't relevant to what we're doing. And as I said, first half of this year, you know, as we got into the second quarter, we weren't taking advantage of this new capacity that we had.

Speaker Change: Because for instance, second half of last year, we didn't have the price increases, we didn't have the increased capacity, we didn't have the automation equipment.

Ted Karkus: And as I said, in the first half of this year, you know, as we got into the second quarter, we weren't taking advantage of this new capacity that we had. And we weren't taking advantage of the price increase we had. And We got these two large customers, but one of them didn't even start giving us business. I believe they're now just starting to give us business in the third quarter. And the other one which gave us some business, but it wasn't a lot because it takes time to ramp up.

Speaker Change: So...

Speaker Change: Last year second half really isn't relevant to what we're doing and as I said first half of this year You know as we got into the second quarter We weren't taking advantage of this new capacity that we had and we weren't taking advantage of the price increase we had and we got these two large customers

Unknown Executive: And we weren't taking advantage of the price increase we had. And we got these two Lord's customers, but one of them didn't even start giving us business. I believe they're now just starting to give us business in the third quarter. And the other one which gave us some business who wasn't alive because it takes time to ramp up. Once somebody gives you an order, you know, you have to perfect the product.

Speaker Change: But one of them didn't even start giving us business. I believe they're now just starting to give us business in the third quarter

Ted Karkus: Once somebody gives you an order, you know, you have to perfect the product, you have to perfect the manufacturing process, and then it could take time until you actually ramp it up. So for all these reasons, I'm more than happy to explain this in more detail in the Q&A. So if I haven't fully explained it, don't be shy.

Ted Karkus: And the other one which gave us some business who wasn't alive because it takes time to ramp up. Once somebody gives you an order, you know, you have to perfect the product. You have to perfect the manufacturing it. And then it could take time until you actually ramp it up. So, for all these reasons, I'm more than happy to explain this in more detail in the Q and A. So if I haven't fully explained it, don't be shy. You can ask more questions about it. Our business at Formalize is exploding right now. We are going to have a big quarter at Formalize is not even a question.

Speaker Change: and the other one which gave us...

Speaker Change: Some business it wasn't a lot because it takes time to ramp up when somebody gives you an order You know you have to perfect the product you have to perfect the manufacturing it

Ted Karkus: You can ask more questions about it. Our business at PharmaLabs is exploding right now. We are going to have a big quarter at PharmaLabs. It's not even a question.

Unknown Executive: You have to perfect the manufacturing it. And then it could take time until you actually ramp it up. So for all these reasons, I'm more than happy to explain this in more detail in the Q and A. So if I haven't fully explained it, don't be shy. You can ask more questions about it. Our business at formalize is exploding right now. We are going to have a big quarter at formalize is not even a question.

Speaker Change: and then it could take time until you actually ramp it up.

Speaker Change: So, for all these reasons, I'm more than happy to explain this in more detail in the Q&A. So, if I haven't fully explained it, don't be shy. You can ask more questions about it. Our business at FarmLoss is exploding right now.

Ted Karkus: Okay, so put any concerns or worries aside. And then, you know, now we can talk about formalizing the business as opposed to, you know, the second, second quarter. Everything on this slide is accurate. By the way, this whole presentation slide is now being posted to our website. This slide, some of the slides have been updated, or the Nebula Genomics slide has been updated for all the things going on there so.

Ted Karkus: Okay. So put any concerns or worry aside. And then, you know, now we can talk about formalize the business as opposed to, you know, the second quarter. Everything on the slide is accurate.

Speaker Change: We are going to have a big quarter at Farmalaz. It's not even a question, okay? So put any concerns or worries aside, and then, you know, now we can talk about Farmalaz, the business, as opposed to, you know, the second quarter.

Unknown Executive: Okay. So put any concerns or worry aside. And then, you know, now we can talk about formalize the business as opposed to, you know, the second quarter. Everything on the slide is accurate. By the way, this whole presentation slide is now being posted to our website. This slide, some of the slides have been updated or nebula genomic slide has been updated for all the things going on there. So look, to me, the most important thing, well, there's several important things with formalize.

Ted Karkus: By the way, this whole presentation slide is now being posted to our website. This slide, some of the slides have been updated or Nebula Genomic slide has been updated for all the things going on there. So look, to me, the most important thing, well, there are several important things with formalize. And by the way, Formalize isn't even the business most excited about. It isn't even the second most important business in our company, but I think realistically, you know, it could be worth the entire market cap of the company right now. And I've already known publicly we're pursuing strategic alternatives.

Speaker Change: Everything on this slide is accurate. By the way, this whole presentation slide is is now being posted to our website. This slide, some of the slides have been updated, our nebula genomics slide has been updated for all the things going on there. So

Ted Karkus: So, um, look, to me, the most important thing, well, there are several important things about Formlabs. And by the way, Formlabs isn't even the business I'm most excited about. It isn't even the second most important business in our company.

Speaker Change: To me, the most important thing, well, there's several important things with Formulas. And by the way, Formulas isn't even the business I'm most excited about. It isn't even the second most important business in our company. But I think realistically,

Unknown Executive: And by the way, formalize isn't even the business most excited about. It isn't even the second most important business in our company, but I think realistically, you know, it could be worth the entire market cap of the company right now. And I've already known publicly we're pursuing strategic alternatives. There was a possibility we were negotiating with one large brand. But understand the difference between us selling this whole business to one large brand, and they only would want the capacity for themselves, so they're not going to value our business customers.

Ted Karkus: But I think realistically, it could be worth the entire market capital of the company right now. And I've already announced publicly that we're pursuing strategic alternatives. There was a possibility we were negotiating with one large brand. But understand the difference between us selling this whole business to one large brand. They only would want the capacity for themselves, so they're not going to value our business.

Speaker Change: It could be worth the entire market cap of the company right now. And I've already announced publicly we're pursuing strategic alternatives. There was a possibility we were negotiating with one large brand. But understand the difference between us selling this whole business to one large brand.

Ted Karkus: There was a possibility we were negotiating with one large brand. But understand the difference between us selling this whole business to one large brand. and they only would want the capacity for themselves, so they're not going to value our business customers. So why would I sell it to one large livens brand if a strategic, a private equity or a strategic or somebody that's in the consumer products business that also wants manufacturing for several of their products, they might pay us twice as much for it. So we hired Think Equity; we are pursuing all strategic alternatives. We are pursuing them aggressively. We put together Dex, all that great stuff after first, first days of September. After Labor Day, we're going out full force. Can't make any guarantees, but I would anticipate in the first quarter of the year, of next year, which really isn't very far away, a potentially very large liquidity event which will make everybody very happy. It'll take all the pressure off the company, all the pressure off the numbers will be a different company, and by that time, all the businesses that I am excited about will have developed to the next stage, and that's what would be focused on. And we'll be focused on that potentially with a very large block of cash on our balance sheet, and then we'll be talking about all those types of fun things that we used to talk about, you know, dividends and stock buybacks and all that great stuff.

Speaker Change: They only would want the capacity for themselves, so they're not going to value our business customers.

Ted Karkus: So why would I sell it to one large license brand if a strategic, a private equity firm, or a strategic, or somebody that's in the consumer products business that also wants manufacturing for several of their products, they might pay us twice as much for it? So we hired Think Equity. We are pursuing all strategic alternatives.

Speaker Change: So why would I sell it to one large Lozenge brand?

Unknown Executive: So why would I sell it to one large livens brand if a strategic, a private equity or a strategic or somebody that's in the consumer products business that also wants manufacturing for several of their products, they might pay us twice as much for it. So we hired Think Equity, we are pursuing all strategic alternatives, we are pursuing them aggressively, we put together Dex, all that great stuff after first, first days of September, after Labor Day, we're going out full force, can't make any guarantees, but I would anticipate in the first quarter of the year, of next year, which is really isn't very far away, a potentially a very large liquidity event which will make everybody very happy, it'll take all the pressure off the company, all the pressure off the numbers will be a different company, and by that time, all the businesses that I am excited about will have developed to the next stage, and that's what would be focused on, and we'll be focused on that potentially with a very large block of cash on our balance sheet, and then we'll be talking about all those types of fun things that we used to talk about, you know, dividends and stock buybacks and all that great stuff.

Speaker Change: If a strategic, a private equity, or a strategic, or somebody that's in the consumer products business

Speaker Change: that also wants manufacturing for several of their products, they might pay us twice as much for it.

Ted Karkus: We are pursuing them aggressively. We put together decks, all that great stuff. After the first few days of September, after Labor Day, we're going out full force.

Speaker Change: So we hired Think Equity. We are pursuing all strategic alternatives. We are pursuing them aggressively. We've put together decks, all that great stuff. After the first days of September , after Labor Day, we're going out full force. Can't make any guarantees.

Ted Karkus: I can't make any guarantees, but I would anticipate in the first quarter of the year of next year, which isn't really very far away, potentially a very large liquidity event, which will make everybody very happy. It'll take all the pressure off the company; all the pressure off the numbers, and it will be a different company. And by that time, all the businesses that I am excited about will have developed to the next stage.

Speaker Change: but I would anticipate in the first quarter of the year of next year, which is really isn't very far away.

Speaker Change: a potentially a very large liquidity event.

Speaker Change: which will make everybody very happy. It'll take all the pressure off the company, all the pressure off the numbers. We'll be a different company. And by that time...

Ted Karkus: And that's what I will be focused on. I will be focused on that, potentially with a very large block of cash on our balance sheet, and then we'll be talking about all those types of fun things that we used to talk about, you know, dividends and stock buybacks and all that great stuff. So that's all to come. I'm sorry if I sound like I'm

Speaker Change: All the businesses that I am excited about will have developed to the next stage and that's what would be focused on and will be focused on that potentially with a very large block of cash.

Ted Karkus: So that's all to come. I'm sorry if I sound excited or optimistic. I know everybody's upset about the stock price. I don't control the stock market; I can only tell you that me and my management team, we are building significant value in our company, in the assets of the company, and I'm really excited about what we're working on. If I went too fast, that's not far from less; happy in the Q&A to go into more.

Ted Karkus: I know everybody's upset about the stock price, I don't control the stock market. I can only tell you that, with my management team, we are building significant value in our company through access to the company, and I'm really excited about what we're working on. If I went too fast, that formula is happy in the Q and A to go in. And in, in, in, in, in, in, in, Okay.

Unknown Executive: So that's all to come. I'm sorry if I sound excited or optimistic, I know everybody's upset about the stock price, I don't control the stock market, I can only tell you that me and my management team, we are building significant value in our company, in the assets of the company, and I'm really excited about what we're working on. If I went too fast, that's not far from less, happy in the Q&A to go into more.

Speaker Change: excited or optimistic. I know everybody is upset about the stock price. I don't control the stock market. I can only tell you that me and my management team, we are building significant value in our company, in the assets of the company, and I'm really excited about what we're working on.

Speaker Change: If I went too fast, that formalized, happy in the Q&A to go into more.

Ted Karkus: Okay, oh, you know what, I have to go back to formalize for a moment, just a couple more bullet points. So line one is operating in a capacity; we're estimating 14 to 60 million revenues and 5 plus million in profits over the next 12 months. That's just for line one. That doesn't include any contribution from line two. Now, I don't know exactly the timing of not only when you install line two, but then hire the people for line two and then get in new business for line two. You know, it's going to be bumpy. Any new business is bumpy.

Ted Karkus: Oh, you know what? I have to go back and formalize for a moment. Just a couple more bullet points. So line one is operating in a capacity where we estimate 14 to 16 million revenues and five plus million in profits over the next 12 months. That's just for line one; that doesn't include any contribution from line two.

Speaker Change: Okay. Oh, you know what? I have to go back to FarmLabs for a moment, though. Just a couple more bullet points.

Ted Karkus: Now, I don't know exactly the timing of not only when you install line two, but then hire the people for line two, and then get a new business for line two. You know, it's gonna be bumpy, just like any new business is bumpy. So think of line two as a business where the first six months are bumpy. So I don't know exactly how that plays out, but we're going to do these numbers without line two.

Unknown Executive: Okay, oh, you know what, I have to go back to formalize for a moment, just a couple more bullet points. So line one is operating in a capacity, we're estimating 14 to 60 million revenues and 5 plus million in profits over the next 12 months, that's just for line one. That doesn't include any contribution from line two. Now, I don't know exactly the timing of not only when you install line two, but then hire the people for line two and then get in new business for line two, you know, it's going to be bumpy.

Speaker Change: So, why am I one of them?

Speaker Change: Operating in a capacity, we're estimating 14 to 60 million revenues and 5 plus million

Ted Karkus: So any contribution from line two is going to increase those numbers. The other thing I can tell you is that since the time that our team put these projections together for farm life for the next 12 months, things are going better. Ted, no guts.

Speaker Change: and Prophets over the next 12 months. That's just for line one.

Speaker Change: That doesn't include any contribution from Line 2.

Speaker Change: Now, I don't know exactly the timing of not only when you install Line 2, but then hire the people for Line 2, and then get in new business for Line 2. You know, it can be bumpy. Any new business is bumpy, so think of Line 2.

Ted Karkus: So think of line two as a business where the first six months is bumpy. So I don't know exactly how that plays out, but we're going to do these numbers without line two. So any contribution from line two is going to increase those numbers. The other thing I can tell you is that since the time that our team put these projections together for formalize for the next 12 months, things are going better than those estimates. So no guarantees in numbers for looking statements for looking statements, but I am very confident we're going to have a great 12 months.

Unknown Executive: Any new business is bumpy. So think of line two as a business where the first six months is bumpy. So I don't know exactly how that plays out, but we're going to do these numbers without line two. So any contribution from line two is going to increase those numbers. The other thing I can tell you is that since the time that our team put these projections together for formalize for the next 12 months, things are going better than those estimates.

Speaker Change: as a business where the first six months is bumpy. So, I don't know exactly how that plays out, but we're going to do these numbers without line two. So, any contribution from line two is going to increase those numbers. The other thing I can tell you is that since the time that our team put these projections together for formalized for the next 12 months, things are going better.

Ted Karkus: So no guarantees in numbers, forward-looking statements, forward-looking statements, but I am very confident we're gonna have a great 12 months. I'm very confident we're gonna have a great. Six months at Formal.

Speaker Change: Then those estimates.

Speaker Change: So, no guarantees in numbers, forward-looking statements, forward-looking statements, but I am very confident we're going to have a great 12 months. I'm very confident we're going to have a great six months at Pharmalus. I'm very confident we're going to have a great quarter at Pharmalus.

Unknown Executive: So no guarantees in numbers for looking statements for looking statements, but I am very confident we're going to have a great 12 months. I'm very confident we're going to have a great six months at formalize. I'm very confident we're going to have a great quarter at formalize, right? So that's on formalize. Let's move forward now. Nebula genomics. And again, ask questions in the Q&A if you need me to cover more in formalize.

Ted Karkus: I'm very confident we're going to have a great six months at Formalize. I'm very confident we're going to have a great quarter at Formalize, right? So that's on formalize.

Ted Karkus: If I'm very confident, we're going to have a great quarter at Formal. Right, so that's on formless. Let's move forward now. Nebula Genomics.

Ted Karkus: Let's move forward now. Nebula Genomics. And again, ask questions in the Q&A if you need me to cover more in formalize. Okay. Here we I'm explaining what net before read the slide presentation. But this is important that I'm going to point out that I don't think I have in the past to give you a little perspective. George Church, we're opening up the field of genomics professor to Harvard. He and two of his PhD Harvard students founded Nebula; we acquired it. They built it based on a strategy using scientific minds to market to other science-like-minded people.

Speaker Change: All right, so that's on PharmaOS. Let's move forward now. Nebula Genomics. And again, ask questions in the Q&A if you need me to cover more on PharmaOS.

Ted Karkus: And again, ask questions in the Q&A if you need me to cover more on formless. Okay, so here we go. I'm explaining what to read next, read the slide presentation about it. But this is important that I'm going to point out that I don't think I have in the past to give you a little background, George Church, world renowned in the field of genomics, professor at Harvard, he and two of his PhD Harvard students founded Nebula; we acquired it, they built it, based on a strategy using scientific minds to market to other like-minded people.

Speaker Change: Okay, here we go.

Unknown Executive: Okay. Here we I'm explaining what net before read the slide presentation. But this is important that I'm going to point out that I don't think I have in the past to give you a little perspective. George Church, we're opening up the field of genomics professor to Harvard, he and two of his PhD Harvard students founded Nebula, we acquired it. They built it based on a strategy using scientific minds to market to other science-like-minded people.

Speaker Change: Go!

Speaker Change: I'm

Speaker Change: [inaudible]

Speaker Change: explaining what next for read read the slide presentation found it but this is important that I'm going to point out that I don't think I have in the past to give you a little perspective

Speaker Change: George Church, world-renowned field of genomics, professor at Harvard. He and two of his PhD Harvard students founded Nebula. We acquired it. They built it.

Speaker Change: based on a strategy using scientific minds

Ted Karkus: Understand that it's a very, very small percentage of the population; their focus was on their 30X whole genome sequencing product, which is a great product. But we have a 1x product, which is a fantastic product. You have to think of the 1X product as the Mercedes Benz of DNA sequencing products because the 1X studies your entire DNA versus an ancestry test that studies less than 1% of your DNA. So compare our whole genome sequence in one X test to an ancestry test that blows it out of the water. A thousand to 5,000 times more data points, so there's no comparison in the test.

Ted Karkus: Understand, it's a very, very small percentage of the population. Their focus was on their 30x whole genome sequencing product, which is a great product. But we have a 1X product, which is a fantastic product. It is, you have to think of the 1X product as the Mercedes-Benz of sequencing products, of DNA sequencing products, because the 1X studies your entire DNA versus an ancestry test; it studies less than 1% of your DNA. So compare our whole genome sequencing, 1X test to an ancestry test; it blows it out of the water, 1,000 to 5,000 times more data points.

Speaker Change: to market to other science like-minded people. Understand it's a very, very small percentage of the population. Their focus was on their 30X whole genome sequencing product, which is a great product.

Unknown Executive: Understand, it's a very, very small percentage of the population. Their focus was on their 30 X whole genome sequencing product, which is a great product. But we have a 1X product which is a fantastic product. It is, you have to think of the 1X product as the Mercedes-Benz of sequencing products, of DNA sequencing products, because the 1X studies your entire DNA versus an ancestry test, it studies less than 1% of your DNA.

Speaker Change: but we have a 1x product

Speaker Change: which is a fantastic product. It is.

Speaker Change: You have to think of the 1X product as the Mercedes-Benz of sequencing products, of DNA sequencing products, because the 1X

Speaker Change: studies your entire DNA versus an ancestry test that studies less than 1% of your DNA. So compare our whole genome sequencing 1X test to an ancestry test that blows it out of the water. 1,000 to 5,000 times more data points.

Unknown Executive: So compare our whole genome sequencing, 1X test to an ancestry test, it blows it out of the water, 1,000 to 5,000 times more data points. Like there's no comparison in the test. And the 1X test is so much less expensive than the 30 X, but the founders of our company didn't focus the company on the 1X product, which is actually a fantastic product. We spent the last eight months revamping our entire go-to-market strategy.

Ted Karkus: Like there's no comparison in the test. And the 1X test is so much less expensive than the 30X, but the founders of our company didn't focus the company on the 1X product, which is actually a fantastic product. We spent the last eight months revamping our entire go-to-market strategy. The other complicated part about this is the B2B; a lot of those companies that reached out to us earlier in the year are very interested, but they don't have their act together. These are all new businesses. They're trying to figure this out as well. And the other problem is if we don't sell the subscriptions, that's where most of our profit is.

Ted Karkus: And the one x test is so much less expensive than the 30 x. But the founders of our company didn't focus the company on the one x product, which is actually a fantastic product. We've spent the last eight months revamping our entire go-to-market strategy. The other complicated part about this is the B2B. A lot of those companies that reached out to us earlier in the year are very interested, but they don't have their act together. These are all new businesses.

Speaker Change: like there's no comparison in the test and the 1x test is so much less expensive than the 30x but the founders of our company didn't focus the company on the 1x product which is actually a fantastic product

Speaker Change: We've spent the last eight months revamping our entire go-to-market strategy.

Ted Karkus: They're trying to figure this out as well. And the other problem is that if we don't sell the subscriptions, that's where most of our profit is. It's not, it's not in selling the sequencing; it's in selling the subscription. That's where our profit margins are enormous. With our direct-to-consumer business, we can now do both, especially with our One X product. We can make a lot of money selling it for an incredibly low price, make a lot of money, and then make an enormous amount of money on our subscription.

Speaker Change: The other complicated part about this is the B2B, a lot of those companies...

Unknown Executive: The other complicated part about this is the B2B, a lot of those companies that reached out to us earlier in the year are very interested, but they don't have their act together. These are all new businesses. They're trying to figure this out as well. And the other problem is if we don't sell the subscriptions, that's where most of our profit is. It's not it's not in selling the sequencing that's in selling the subscription.

Speaker Change: that reached out to us earlier in the year, are very interested, but they don't have their act together. These are all new businesses. They're trying to figure...

Speaker Change: This out as well.

Ted Karkus: It's not, it's not in selling the sequencing; that's in selling the subscription. That's where our profit margins are enormous. With our direct-to-consumer, we can now do both, especially with our 1X product. We can make a lot of money, sell it incredibly low price, make a lot of money, and then make an enormous amount of money on our subscription. And so the problem is the platform and the business was never focused properly, and the marketing was never done properly. We have hired; we have, I shouldn't say hired, we have retained the services of one of the best social media players.

Speaker Change: And the other problem is if we don't sell the subscriptions, that's where most of our profit is. It's not in selling the sequencing, it's in selling the subscription. That's where our profit margins are enormous. With our direct-to-consumer...

Unknown Executive: That's where our profit margins are enormous. With our direct-to-consumer, we can now do both, especially with our 1X product, we can make a lot of money, sell it incredibly low price, make a lot of money, and then make an enormous amount of money on our subscription. And so the problem is the platform and the business was never focused properly, and the marketing was never done properly. We have hired, we have, I shouldn't say hired, we have retained the services of one of the best social media players.

Speaker Change: We can now do both, especially with our ONEx product.

Speaker Change: We can make a lot of money, sell at an incredibly low price, make a lot of money, and then make an enormous amount of money on our subscription.

Ted Karkus: And so the problem is the platform and the business was never focused properly, and the marketing was never done properly. We have hired, we have, can say higher, we have retained the services of one of the best Social Media players. He was the Chief Business Officer of Barstool Sports. He's now with a 10 p.m. Curfew. His name's Sue Hollinsett.

Speaker Change: and so the problem is the platform and the business was never focused properly and the marketing was never done properly, we have

Speaker Change: hired, we have

Speaker Change: I shouldn't say hired, we have retained the services.

Ted Karkus: He was the Chief Business Officers of Barstool Sports. He's now at 10 p.m. Curfew. His name's Stu Hollins. He's working very closely with Jason Carcass in our management team at Nebula. I'm so excited for what they are doing. I think of myself as young, but I'm not young in terms of how social media is developed. That's really more a young person's game. They may sound a little odd, but what they are working on, you got to understand Barstool Sports, just in the reach of Barstool Sports and all the influencers and that whole social media platform.

Speaker Change: of one of the best.

Speaker Change: social media players, he was the chief business officer of Barstool Sports, he's now with 10pm curfew.

Ted Karkus: He's working very closely with Jason Karkus in our management team at Nebula. I'm so excited about what they are doing. I think of myself as young, but I'm not young in terms of how social media is developed.

Unknown Executive: He was the Chief Business Officers of Barstool Sports. He's now at 10 p.m. Curfew. His name's Stu Hollins. He's working very closely with Jason Carcass in our management team at Nebula. I'm so excited for what they are doing. I think of myself as young, but I'm not young in terms of how social media is developed. That's really more a young person's game. They may sound a little odd, but what they are working on, you got to understand Barstool Sports, just in the reach of Barstool Sports and all the influencers and that whole social media platform.

Speaker Change: His name is Stu Hollinsett. He's working very closely with Jason Karkus and our management team at Nebula. I'm so excited for what they are doing.

Ted Karkus: That's really more a young person's thinking. They may sound a little odd, but what they are working on, you've got to understand Barstool Sports and all the influencers and that whole social media platform. Well, that effort is what we're bringing to the table with our various products. We have a world-class whole genome sequencing product. We have a world-class laboratory. So that's part of the problem also.

Speaker Change: You know, I'm an old, I think of myself as young, but I'm not young in terms of how social media is developed. That's really more a young person's game.

Ted Karkus: Well, that effort is what we're bringing to the table with our various products. We have a world-class whole genome sequencing product. We have a world-class laboratory. Part of the problem also, besides formalized, we built out this world-class lab, but we didn't have the business to support it. That's the other reason for the losses of the company currently. We're a development-states company losing money, but I like to think that the money we're losing is an investment in building significant value in the company. In formalized, We are now taking a business that we invested in. We bought more equipment.

Unknown Executive: Well, that effort is what we're bringing to the table with our various products. We have a world-class whole genome sequencing product. We have a world-class laboratory. Part of the problem also, besides formalized, we built out this world-class lab, but we didn't have the business to support it. That's the other reason for the losses of the company currently. We're a development-states company losing money, but I like to think that the money we're losing is an investment in building significant value in the company.

Speaker Change: to the table with our various products. We have a world-class whole-genome sequencing product. We have a world-class laboratory. So part of the problem also...

Ted Karkus: Besides PharmaLabs, we built out this world-class lab, but we didn't have the business to support it. That's the other reason for the losses of the company currently, but we're a development-based company losing money. But I like to think that the money we're losing is an investment in building significant value in the company.

Speaker Change: Besides pharma losses, we built out this world-class lab, but we didn't have the business to support it. That's the other reason for the losses of the company currently, but I understand we're a development-stage company losing money, but I like to think that the money we're losing is an investment in building significant value in the company. So in pharma loss,

Ted Karkus: We are now taking a business that we invested in; we bought more equipment, we built it out, took on the expense of that. But now, the value is going to, I believe, pay itself back to us 10 times over in a matter of months, whether that's four months or six months or seven months or whatever. And again, not a guarantee, but I'm highly optimistic that, you know, we should have a significant transaction in the first quarter next year, if not sooner. And so by the same token, the beauty of our company is we have various assets and various stages of development, formalize the most developed. It's already doing a lot of these things.

Unknown Executive: In formalized, We are now taking a business that we invested in. We bought more equipment. We built it out, took on the expense of that. But now the value is going to, I believe, pay itself back to us 10 times over in a matter of months, whether that's four months or six months or seven months or whatever. And again, not a guarantee, but I am highly optimistic that, you know, we should have a significant transaction, you know, in the first quarter next year, if not soon.

Ted Karkus: We built it out, took on the expense of that. But now the value is going to, I believe, pay itself back to us 10 times over in a matter of months, whether that's four months, six months, or seven months, or whatever. And again, not a guarantee, but I am highly optimistic that, you know, we should have a significant transaction, you know, in the first quarter next year, if not soon.

Speaker Change: We are now taking a business that we invested in, we bought more equipment, we built it out.

Speaker Change: took on the expense of that. But now the value is going to, I believe, pay itself back to us 10 times over in a matter of months, whether that's four months or six months or seven months or whatever. And again, not a guarantee, but I'm highly optimistic that, you know, we should have a significant transaction.

Ted Karkus: And so, by the same token, the beauty of our company is we have very assets and various stages of development, formalizes the most developed. It's already doing a lot of business. Nebula Genomics is doing a small amount of business, but we believe that that's about to go. It may wear above slowly for a couple of months. All right, it doesn't happen overnight. You know, look at all the great products out there. You know, the ones that come to my mind, there is like beverages, you know, like Prime, Celsius Holdings, you know, Celsius Holdings over five years, stock went from a dollop to $90.

Speaker Change: in the first quarter of next year if not sooner. And so by the same token, the beauty of our company is we have various assets in various stages of development. Farmalaz is the most developed. It's already doing a lot of business.

Unknown Executive: And so by the same token, the beauty of our company is we have very assets and various stages of development, formalizes the most developed. It's already doing a lot of business. Nebula genomics is doing a small amount of business, but, but we believe that that's about to go. It may wear above slowly for a couple of months. All right, it doesn't happen overnight. You know, look at all the great products out there.

Ted Karkus: Nebula Genomics is doing a small amount of business, but we believe that's about to change. It may ramp up slowly for a couple of months, all right. It doesn't happen overnight, you know, look at all the great products out here, the ones that come to my mind, there are like beverages, you know, like Prime, selfie as holdings, you know, selfie as holdings. Over five years, their stock went from $1 to $90. Crazy.

Speaker Change: Nebula Genomics is doing a small amount of business, but we believe that's about to go. It may wear above slowly for a couple of months.

Speaker Change: Alright, it doesn't happen overnight, you know, look at all the great products out there, you know, the ones that come to my mind There is like beverages

Unknown Executive: You know, the ones that come to my mind, there is like beverages, you know, like prime, Celsius holdings, you know, Celsius holdings over five years, stock went from a dollop to $90. It's crazy. So these things take time. It's not going to happen overnight. I think we have a great product. I think we have a great social media platform that's about to launch within weeks. If not days, I will do a substantive update.

Speaker Change: You know, like Prime, Celsius Holdings, you know, Celsius Holdings over five years stock went from $1 to $90, crazy.

Ted Karkus: It's crazy. So, these things take time. It's not going to happen overnight. I think we have a great product. I think we have a great social media platform that's about to launch within weeks. If not days, I will do a substantive update. At some point in the future, once it launches, it's a soft launch. We're going to tweak it a little bit. And then a month or two from now, we're going to go hog wild. All right. So look, you know, all the assets at Nebula, you know, you know what we have? We have a lot behind this.

Ted Karkus: So these things take time. It's not going to happen overnight. I think we have a great product. I think we have a great social media platform that's about to launch within weeks. If not days. I will do a substantive update at some point in the future. Once it launches, we're going to tweak it a little bit.

Speaker Change: So, these things take time, it's not going to happen overnight. I think we have a great product. I think we have a great social media platform that's about to launch within weeks, if not days. I will do a substantive update at some point in the future once it launches. It's a soft launch.

Ted Karkus: And then a month from now, or two from now, we're going to go hog wild. All right. So look, you know, all the assets at Nebula, you know, you know what we have. We have a lot behind this. I can go into more detail in the Q&A. Obviously, we have what we believe is the best proprietary bioinformatics platform in the world for reporting results. And what you have to understand about our reporting is that the reporting is only as good as the database. We have one of the best, most in-depth, largest sequencing databases in the world. Again, it's the equivalent of 150 million ancestors.

Unknown Executive: At some point in the future, once it launches, it's a soft launch. We're going to tweak it a little bit. And then a month or two from now, we're going to go hog wild. All right. So look, you know, all the assets at Nebula, you know, you know what we have? We have a lot behind this. I can go into more detail in the Q and A. Obviously, we have what we believe is the best proprietary bioinformatics platform in the world for reporting results.

Speaker Change: We're going to tweak it a little bit, and then a month from now, or two from now, we're going to go hog wild.

Speaker Change: Alright, so look, you know all the assets at Nebula. You know what we have. We have a lot behind this. I can go into more detail in the Q&A. Obviously, we have what we believe is the best proprietary bioinformatics platform in the world.

Ted Karkus: I can go into more detail in the Q and A. Obviously, we have what we believe is the best proprietary bioinformatics platform in the world for reporting results. And what you have to understand about our reporting, the reporting is only as good as the database. We have one of the best, most in-depth, largest sequencing databases in the world. Again, it's the equivalent of 150 million ancestry tests. So just imagine the quality of the reports, the number of reports, how indebted it is. And we now provide an ancestry test just as good as the SS companies.

Speaker Change: for reporting results. And what you have to understand about our reporting

Unknown Executive: And what you have to understand about our reporting, the reporting is only as good as the database. We have one of the best most in depth, largest sequencing databases in the world. Again, it's the equivalent of 150 million ancestry test. So just imagine the quality of the reports, the number of reports, how indebted it is. And we now provide an ancestry test just as good as the SS companies. And in addition to that, we now have a special program that we're going to ramp up with with our social media platform.

Speaker Change: The reporting is only as good as the database. We have one of the best, most in-depth, largest sequencing databases in the world. Again, it's the equivalent of 150 million ancestry tests.

Ted Karkus: So just imagine the quality of the reports, the number of reports, how in-depth it is. And we now provide an ancestry test. Chefs is as good as the ancestry companies.

Speaker Change: So just imagine the quality of the reports, the number of reports, how indebted it is, and we now provide an Ancestry test.

Ted Karkus: And in addition to that, we now have a special program that we're going to ramp up with our social media platform, which I'll talk more about in a few weeks. In the meantime, we can take your ancestry test that you get from 23andme or ancestry.com or one of the other companies, we can upload your data, and we can give you a phenomenal in-depth health report, again, based on our So just imagine taking the data to upload it; it costs us very little. We can offer you it. We can offer the reports for less than what the ancestry companies are offering their reports for. We can offer you health reports for less than other ancestry companies.

Ted Karkus: And in addition to that, we now have a special program that we're going to ramp up with our social media platform. Once again, I'll talk more about, you know, in a few weeks or a month or two, if not, if not sooner. We can take your ancestry test that you get from 23andMe. Or Ancestry.com or one of the other companies, we can upload your data. And we can give you a phenomenal in depth health report. Again, based on our genomic database, which is based on sequencing of patients from 100, I shouldn't say patients, customers from 130 countries.

Speaker Change: Chess is good!

Speaker Change: as the accessory companies, and in addition to that...

Speaker Change: We now have a special program that we're going to wrap up with our social media platform, which again, I'll talk more about...

Unknown Executive: Once again, I'll talk more about, you know, in a few weeks or a month or two, if not, if not sooner. We can take your ancestry test that you get from 23 and me. Or ancestry.com or one of the other companies, we can upload your data. And we can give you a phenomenal in depth, health report. Again, based on our genomic database, which is based on sequencing of patients from 100, I shouldn't say patients, customers from 130 countries.

Speaker Change: You know, in a few weeks or in a month or two, if not sooner, we can take your ancestry test that you get from 23 and me or ancestry.com or one of the other companies we can upload your data.

Speaker Change: And we can give you a phenomenal in-depth health report, again, based on our genomic database, which is based on sequencing of patients from 100, I shouldn't say patients, customers from 130 countries.

Ted Karkus: So just imagine taking the data, so it's to upload; of course, is very little. We can offer it. We can offer the reporting for less than what the ancestry companies are offering their reporting for. We can offer you health reports for less than the other ancestry companies. We can offer you a subscription for less than the other ancestry companies and provide more in-depth reports, more accurate reports, and more of them. This is a phenomenal product. It's called our DNA Expand product where we're expanding on your ancestry test. So we have all these really cool things going on with Nebula.

Speaker Change: So, just imagine taking the data to upload, it costs us very little. We can offer it. We can offer the reporting for less than what the ancestry companies are offering their reporting for. We can offer you health reports for less than the other ancestry companies. We can offer you a subscription for less than the other ancestry companies.

Unknown Executive: So just imagine taking the data so it's to upload, of course, is very little. We can offer it. We can offer the reporting for less than what the ancestry companies are offering their reporting for. We can offer you health reports for less than the other ancestry companies. We can offer you a subscription for less than the other ancestry companies and provide more in depth reports, more accurate reports and more of them.

Ted Karkus: We can offer you a subscription for less than the other ancestry companies and provide more in-depth reports, more after reports, and more of them. This is a phenomenal product that's called our DNA expand product where we're expanding on your ancestry test. So we have all these really cool things going on with Nebula. I'm really excited about it.

Speaker Change: and provide more in-depth reports, more accurate reports, and more of them. This is a phenomenal product that's called our DNA Expand product, where we're expanding on your Ancestry test.

Unknown Executive: This is a phenomenal product. It's called our DNA expand product where we're expanding on your ancestry test. So we have all these really cool things going on with Nebula. I'm really excited about it. I'm sure people are a little frustrated that we didn't ramp up in the last six months, but we have a really beautiful program going forward with Nebula. Prophase Bioform. Let's touch on that a little bit. All right, equivir.

Ted Karkus: I'm really excited about it.

Ted Karkus: I'm sure people are a little frustrated that we didn't ramp up in the last six months, but we have a really beautiful program going forward with Nebula.

Ted Karkus: I'm sure people are a little frustrated that we didn't ramp up in the last six months, but we have a really beautiful program going forward with Nebula. All right. Prophase Biopharma. Let's touch on that a little bit. All right, Equivir.

Speaker Change: So we have all these really cool things going on with Nebula. I'm really excited about it. I'm sure people are a little frustrated that we didn't ramp up in the last six months, but we have a really beautiful program going forward with Nebula.

Ted Karkus: Prophase bioform. Let's touch on that a little bit. All right, equivir.

Speaker Change: All right

Speaker Change: Prophase Biopharma. Let's let's touch on that a little bit. All right, Equivir.

Ted Karkus: So I'm sorry, we're not talking about Equivir yet; that'll be next. Those were in my notes. Are these smartest offageal cancer tests? I've gone through all this before. I'll talk about it more in the Q&A. We hired a world-class consulting firm, FHC, Dr. Shafik, Dr. Yeager. These gentlemen have worked on some of the best world-class cancer tests and other diagnostic tests out there, taking them from virtually scratch and turning them into large companies. Now, we have a couple of different approaches we can take with them to be smarter offageal cancer tests. And again, I will just give you a couple of quick highlights.

Speaker Change: So, I'm sorry, we're not talking about Equivir yet. That'll be next. Those were in my notes. Our B-Smart esophageal cancer test.

Unknown Executive: So I'm sorry, we're not talking about equivir yet, that'll be next. Those were in my notes. Are these smartest offageal cancer tests? I've gone through all this before, I'll talk about it more in the Q&A. We hired a world-class consulting firm, FHC, Dr. Shafik, Dr. Yeager. These gentlemen have worked on some of the best world-class cancer tests and other diagnostic tests out there, taking them from virtually scratch and turning them into large companies.

Ted Karkus: So, I'm sorry, we're not talking about Equivir yet. That'll be next. Those were in my notes. Our B-Smart esophageal cancer.

Ted Karkus: I've gone through all this before, and I'll talk about it more in the Q&A. We hired a world-class consulting firm, FHC, Drs. Hyatt, Dr. Shafiq, and Dr. Yeager. These gentlemen have worked on some of the best world-class cancer tests and other diagnostic tests out there, taking them from Virtually Scratch and turning them into large companies. Now, we have a couple of different approaches we can take where there would be smarter sausages. And, again, I will just give you a couple of quick highlights. There are blood tests out there that are highly inaccurate. It's not possible for blood tests to be accurate.

Speaker Change: I've gone through all this before. I'll talk about it more in the Q&A. We hired a world-class consulting firm, FHC, Drs. Hyatt, Dr. Shafik, Dr. Yeager.

Speaker Change: These gentlemen have worked on some of the best world-class

Speaker Change: cancer tests and other tests, diagnostic

Speaker Change: from virtually scratch and turning them into large companies.

Ted Karkus: And the reason is that by the time you get signals in your blood, they have esophageal cancer. At the same time, you can have other viruses, other diseases, other things going on in your body that show up in your blood that will give you a false positive. It'll look like esophageal cancer, but it's not. So a blood test is a great first test, for a sausage. You'll catch her, just because it's so easy to do, you can do it in the doctor's office, and it comes back positive.

Speaker Change: Now, we have a couple of different approaches we can take for them to be smart and soft as you'll

Unknown Executive: Now, we have a couple of different approaches we can take with them to be smarter offageal cancer tests. And again, I will just give you a couple of quick highlights. There are blood tests out there that are highly inaccurate. It's not possible for blood tests to be accurate. And the reason is, by the time you get signals in your blood, they have a softageal cancer, it's too late. At the same time, you can have other viruses, other disease, other things going on in your body that shows up in your blood that will give you a false positive that will look like a softageal cancer.

Ted Karkus: There are blood tests out there that are highly inaccurate. It's not possible for blood tests to be accurate. And the reason is, by the time you get signals in your blood, they have an esophageal cancer, it's too late. At the same time, you can have other viruses, other disease, other things going on in your body that shows up in your blood that will give you a false positive that will look like a softageal cancer. It's not. So a blood test is a great first test for softageal cancer just because it's so easy to do. You can do it in the doctor's office.

Speaker Change: And, again, I will just give you a couple of quick highlights. There are blood tests out there that are highly inaccurate. It's not possible for a blood test to be accurate. And the reason is, by the time you get signals in your blood,

Speaker Change: They have a sausage, you'll catch us too late.

Speaker Change: At the same time, you can have other viruses, other diseases, other things going on in your body that shows up in your blood that'll give you a false positive. It'll look like esophageal cancer. It's not. So a blood test is a great first test.

Unknown Executive: It's not. So a blood test is a great first test for softageal cancer just because it's so easy to do. You can do it in the doctor's office. And if it comes up positive, that will motivate the doctor to prescribe to the patient to get an endoscopy, where we come in as if you get an endoscopy. So all these tests that take place before the endoscopy only motivate you to then go to the standard care, which is the endoscopy.

Ted Karkus: And if it comes up positive, that will motivate the doctor to prescribe to the patient to get an endoscopy, where we come in as if you get an endoscopy. So all these tests that take place before the endoscopy only motivate you to then go to the standard care, which is the endoscopy. What our test does is we make the endoscopy significantly more accurate. Because once you get the endoscopy, our test will tell you it's much more accuracy than what the human eye can tell you just looking at the specimen, the biopsy that comes from the endoscopy. As I always say, two GI's look at the same specimen on the same microscope.

Speaker Change: For esophageal cancer just because it's so easy to do you can do it in the doctor's office and if it comes up positive

Ted Karkus: That'll motivate the doctor to prescribe an endoscopy, where we come in as if you get an endoscopy. So all these tests that take place before the endoscopy only motivate you to then go to the standard of care, which is the endoscopy. What our test does is it makes the endoscopy significantly more accurate because once you get the endoscopy, our test will tell you with much more accuracy than what the human eye can tell you just looking at the specimen, the biopsy that comes from the endoscopy.

Speaker Change: that will motivate the doctor to prescribe to the patient to get an endoscopy, where we come in as if you get an endoscopy. So all these tests that take place before the endoscopy, only motivate you to then go to the standard of care which is the endoscopy.

Speaker Change: What our test does is we make the endoscopy

Unknown Executive: What our test does is we make the endoscopy significantly more accurate. Because once you get the endoscopy, our test will tell you it's much more accuracy than what the human eye can tell you just looking at the specimen, the biopsy that comes from the endoscopy, as I always say, two GI's look at the same specimen on the same microscope. One will tell you about the softageal cancer. The diagnostics related to a softageal cancer right now are simply really bad for a disease that's one of the deadliest cancers in the world.

Speaker Change: is significantly more accurate.

Speaker Change: because once you get the endoscopy, our test will tell you much more accuracy than what the human eye can tell you just looking at the specimen, the biopsy, that comes from the endoscopy, as I always say, 2GIs look good, you know.

Ted Karkus: As I always say, two GI's look at the same specimen, the same microscope. One will tell you how to stop a double cancer, and one will tell you no. The diagnostics related to soft and dual cancer right now are simply really bad for a disease that's one of the deadliest cancers in the world. So just imagine that huge gap for a cancer test for esophageal cancer that actually tells you more accurately whether or not you have cancer.

Ted Karkus: One will tell you about the softageal cancer. The diagnostics related to a softageal cancer right now are simply really bad for a disease that's one of the deadliest cancers in the world. So just imagine that huge gap for a cancer test, for a softageal cancer that actually tells you more accurately whether or not you have cancer. The potential of this is absolutely enormous. And that's why FHC, our consultants, they're very picky who they take out as a customer. And at the same time, we're very careful about it. And it's obviously a match made in heaven.

Speaker Change: [inaudible]

Speaker Change: So just imagine a huge gap.

Unknown Executive: So just imagine that huge gap for a cancer test, for a softageal cancer that actually tells you more accurately whether or not you have cancer. The potential of this is absolutely enormous. And that's why FHC, our consultants, they're very picky who they take out as a customer. And at the same time, we're very careful about it. And it's obviously it's a match made in heaven. So we're going to do things all the right way.

Speaker Change: for a cancer test for esophageal cancer that actually tells you more accurately whether or not you have cancer. The potential of this is absolutely enormous and that's why FHC, our consultants, they're very picky.

Ted Karkus: The potential for this is absolutely enormous. And that's why FHC, our consultants, are very picky about who they take on as a customer. And at the same time, we're very careful about who we want, and it's, honestly, it's a match made in heaven.

Speaker Change: who they take out as a customer and at the same time we're very careful about we want to and it's obviously it's a match made in heaven so we're going to do things all the right way

Ted Karkus: So we're going to do things all the right way. And it goes so far beyond just getting CPT codes. That's kind of simplistic because CPT codes, you know, would it give you the ability to sell the test? It would, but would we get any traction? The other thing that's happening, more importantly, is that the FDA, and honestly, I didn't believe this was going to happen. They're actually taking over control of LDT's laboratory developed test in this thousand. I don't know how they're going to do it. So eventually we're going to have to deal with the FDA anyway, and understand there's several components.

Ted Karkus: So we're going to do things all the right way. And it goes so far beyond just getting CPT codes. That's kind of simplistic. Because CPT codes, you know, would give you the ability to sell the test? It would, but would we get any traction?

Speaker Change: And it goes so far beyond just getting CPT codes, that's kind of simplistic.

Unknown Executive: And it goes so far beyond just getting CPT codes. That's kind of simplistic because CPT codes, you know, would it give you the ability to sell the test? It would, but would we get any traction? The other thing that's happening more importantly is that the FDA, and honestly, I didn't believe this was going to happen. They're actually taking over control of LDT's laboratory developed test in this thousand. I don't know how they're going to do it.

Speaker Change: because CPK calls.

Ted Karkus: The other thing that's happening, more importantly, is that the FDA, and honestly, I didn't believe this was going to happen. They're actually taking over control of LDTs, laboratory-developed testing; there are thousands, you know; I don't know how they're going to do it. So eventually, we're gonna have to deal with the FDA anyway. And understand there are several components. There's the FDA, there's the insurance companies, the payers, and then there's the physician networks who prescribe them.

Speaker Change: you know, would it give you the ability?

Speaker Change: to sell the test? It would, but would we get any traction? The other thing that's happening, more importantly, is that the FDA, and honestly I didn't believe this was going to happen, they're actually taking over control of LDT's laboratory-developed testing. There's thousands, you know, I don't know how they're going to do it.

Ted Karkus: There's the FDA. There's the insurance companies, the payers, and then there's the physician networks who prescribe it. So the physician networks have to subscribe it. We may have a way to fast track. I don't want to get ahead of myself, but we'll be updating to fast track with the FDA as well while we're working on the other avenues. But I don't share; we're working on the other avenues at the same time, bringing in the physician networks and working with the insurance payers. And in fact, it's one of the reasons we brought on a new board of director, a new director, who works at Optum, which is one of the biggest physician networks in the country.

Speaker Change: So eventually we're going to have to deal with the FDA anyway and understand there's several components. There's the FDA There's the insurance companies of the payers and then there's the physician network who prescribe it So the physician networks have to subscribe it They have to know the insurance companies are paying for it. The FDA has to bless it. There are a lot of moving pieces here

Unknown Executive: So eventually we're going to have to deal with the FDA anyway and understand there's several components. There's the FDA. There's the insurance companies, the payers, and then there's the physician networks who prescribe it. So the physician networks have to subscribe it. We may have a way to fast track. I don't want to get ahead of myself, but we'll be updating to fast track with the FDA as well while we're working on the other avenues.

Ted Karkus: So the physician networks have to accept it. They have to know the insurance companies are paying for it. The FDA has to bless it. There are a lot of moving pieces here. The bottom line is FHC. They're the experts. We're working closely together. We're gonna figure out the best game plan.

Speaker Change: The bottom line is FHC, they're the experts. We're working closely together, we're going to figure out the best game plan. And at the same time, we may, I don't want to speak out of turn, we may have a way to fast track

Ted Karkus: And at the same time, we may, I don't wanna speak out of turn, we may have a way to fast track. I don't want to get ahead of myself, but we'll be updating fast track with the FDA as well while we're working on the other avenues. But I understand we're working on other avenues at the same time, bringing in physician networks and working with the insurance payers. And in fact, that's one of the reasons we brought on a new board of directors, a new director who works at Optum, which is one of the biggest physician networks in the country. They have about 20 different major physician networks.

Speaker Change: I don't want to get ahead of myself, but we'll be updating to fast track with the FDA as well while we're working on the other avenues, but I understand we're working on the other avenues at the same time, bringing in the physician networks and working with the insurance payers.

Unknown Executive: But I don't share we're working on the other avenues at the same time, bringing in the physician networks and working with the insurance payers. And in fact, it's one of the reasons we brought on a new board of director, a new director, who works at Optum, which is one of the biggest physician networks in the country. They have like 20 different major physician networks. In fact, we have another director on a board who works in one of those physician networks and he's the one that brought in our other directors actually at Optum, the parent.

Speaker Change: And in fact, that's one of the reasons we brought on a new board of director, a new director, who works at Optum, which is one of the biggest physician networks.

Ted Karkus: In fact, we have another director on our board who works in one of those physician networks, and he's the one that brought in our other director, who's actually at Optum, the parent. So I believe between our connections on our board of directors with FHC and the fact that we have literally a one-of-a-kind esophageal cancer test that is incredibly sorely needed, and it's clearly a multi- You know, I've worked through the numbers before.

Ted Karkus: They have like 20 different major physician networks. In fact, we have another director on a board who works in one of those physician networks, and he's the one that brought in our other directors, actually, at Optum, the parent. So I believe between our connections on our board of directors with FHC and the fact that we have literally a one of one of a kind, a sausage, you'll capture test that is incredibly sorely needed and it's clearly a multi billion dollar target market. You know, I've worked through the numbers before. I'll just show you really quickly.

Speaker Change: in the country. They have like 20 different major physician networks. In fact, we have another director on our board who works in one of those physician networks and he's the one that brought in

Speaker Change: our other directors, actually, at Optum, the parent. So, I believe between our connections on our board of directors...

Unknown Executive: So I believe between our connections on our board of directors with FHC and the fact that we have literally a one of one of a kind, a sausage, you'll capture test that is incredibly sorely needed and it's clearly a multi billion dollar target market. You know, I've worked through the numbers before. I'll just show you really quickly. Our target market, we shouldn't even take out the two million at the bottom. Our target market is our seven million endoscopies a year.

Speaker Change: with FHC.

Speaker Change: and the fact that we have literally a one-of-a-kind esophageal cancer test that is incredibly sorely needed, and it's clearly a multi-billion-dollar target market.

Ted Karkus: I'll just show you really quickly. Our target market, we should even take out the two million at the bottom. Our target market is seven million endoscopies a year. Understand these are endoscopies already taking place. If we only get reimbursed $1,000, we think it's going to be more.

Ted Karkus: Our target market; we shouldn't even take out the two million at the bottom. Our target market is our seven million endoscopies a year. Understand these are endoscopies who are already taking place. If we only got reimbursed $1,000, we think it's going to be more, but even if it's only $1,000, that's a $7 billion dollar market we're going after. With virtually no competition and a test, it's sorely needed. So we're going to do it the right way and understand, you know, our consultants, for example, one of our consultants, I don't know we want to name by name, worked very closely with Garden Health for many, many years and was instrumental in helping turn them into, you know, they got a three or four billion dollar market cap right now at its peak back in 2021. Things are pretty good at 20 billion market.

Speaker Change: You know, I've worked through the numbers before. I'll just show you really quickly. Our target market, we should even take out the 2 million at the bottom, our target market is 7 million endoscopies a year. Understand, these are endoscopies already taking place.

Ted Karkus: But even if it's only $1,000, it's a $7 billion dollar market we're going into, with virtually no competition and a test that's sorely needed. So we're going to do it the right way and understand, you know, our consultants, for example, um, one of our consultants, I don't know who wants to name my name, worked very closely with Garden Health for many, many years and was instrumental in helping turn them into, you know, they got, they have a three or $4 billion market cap right now. At its peak back in 2021, things were pretty good at 20 billion market cap.

Unknown Executive: Understand these are endoscopies who are already taking place. If we only got reimburse $1,000, we think it's going to be more, but even if it's only $1,000, that's a $7 billion dollar market we're going after. With virtually no competition and a test, it's sorely needed. So we're going to do it the right way and understand, you know, our consultants, for example, one of our consultants, I don't know we want to name by name, worked very closely with garden health for many, many years and was instrumental in helping turn them into, you know, they got a three or four billion dollar market cap right now at its peak back in 2021 things are pretty good at 20 billion market.

Speaker Change: If we've only got reimbursed $1,000, we think it's going to be more. But even if it's only $1,000, it's a $7 billion market we're going after.

Speaker Change: with virtually no competition and a test that's sorely needed. So we're going to do it the right way and understand, you know, our consultants, for example.

Speaker Change: one of our consultants, I don't know who wants to name by name, worked very closely with Garden Health.

Speaker Change: for many, many years, and was instrumental in helping turn them into, you know, they have a $3 or $4 billion market cap right now. At its peak back in 2021, things were crazy. They had a $20 billion market cap. My point is, early on, they had a multi-billion dollar market cap. He wants to do the same things for us.

Ted Karkus: My point is early on, they had a multi-billion dollar market cap. He wants to do the same things for us. So forget about multi-billion dollars. A billion dollars is a $50 stock price. Half a billion is a $25 stock price.

Ted Karkus: My point is, early on, they had a multi-billion dollar market. He wants to do the same things for us. So forget about multi billion dollars, billion dollars for $50 stock price, half a billion. It's a $25 stock price. If it takes two years, two to three years. So what? All right, so this is the kind of perspective, and that's just on our soft and jeal cancer test. And that's an addition to the fact that we have our Nebula Genomics business. Finally, I think it's going to ramp up in a big way. And that's an addition to the fact that we have formalized.

Unknown Executive: My point is early on, they had a multi billion dollar market. He wants to do the same things for us. So forget about multi billion dollars, billion dollars for $50 stock price, half a billion. It's a $25 stock price. If it takes two years, two to three years. So what? All right, so this is the kind of perspective and that's just on our soft and jeal cancer test. And that's an addition to the fact that we have our nebula genomics business.

Speaker Change: So forget about multi-billion dollars. A billion dollars is a $50 stock price. Half a billion is a $25 stock price.

Ted Karkus: If it takes two years, two to three years, so what? All right, so this is the kind of perspective. And that's just on our Sofford Julekian test.

Speaker Change: If it takes two years, two to three years, so what?

Ted Karkus: And that's an addition to the fact that we have our nebula genomics business. Finally, I think it's going to ramp up in a big way. And that's an addition to the fact that we have formalized the forwarding, generating a lot of revenues and earnings going forward. And it's highly valuable right now, today, not six months from now.

Speaker Change: Alright, so this is the kind of perspective and that's just on our esophageal cancer test And that's in addition to the fact that we have our nebulous genomics business Finally, I think it's gonna ramp up in a big way and that's in addition to the fact that we have farm allowance It's already generating a lot of revenues and earnings going forward and it's highly valuable right now today Not six months from now. It's highly valuable now with each six months the value of farm allowance goes up

Ted Karkus: It's already generating a lot of revenues and earnings going forward. And it's highly valuable right now, today, not six months from now; highly valuable now. With each six months, the value of formalized goes up. So it's really just a question of how long we hold it on, you know; we could sell it today. We can sell it six months from now, or we can sell 12 months from now. We'll see how it plays out. We'll see what the demand is. We'll see what the pricing is, so on and so forth. The cold, I did the same thing with the Coldies brand, by the way.

Unknown Executive: Finally, I think it's going to ramp up in a big way. And that's an addition to the fact that we have formalized. It's already generating a lot of revenues and earnings going forward. And it's highly valuable right now, today, not six months from now, highly valuable now with each six months, the value of formalized goes up. So it's really just a question of how long we hold it on, you know, we could sell it today.

Ted Karkus: It's highly valuable now; with each six months, the value of formalized goes up. So it's really just a question of how long we hold it on. We could sell it today, we can sell it six months from now, or we can sell it 12 months from now. We'll see how it plays out.

Speaker Change: So it's really just a question of how long we hold it on. You know, we could sell it today. We can sell it six months from now or we can sell it 12 months from now.

Ted Karkus: We'll see what the demand is. We'll see what the pricing is. So on and so forth. The Colby, I did the same thing with the Colby's brand, by the way, and in one year.

Unknown Executive: We can sell it six months from now or we can sell 12 months from now. We'll see how it plays out. We'll see what the demand is. We'll see what the pricing is, so on and so forth. The cold, I did the same thing with the coldies brand, by the way. And in one year. I was offered $20 to $25 million for it, 18 months later I sold it for $50 million.

Speaker Change: We'll see how it plays out, we'll see what the demand is, we'll see what the pricing is, so on and so forth. The Kaldi, I did the same thing with the Kaldi's brand by the way, and in one year...

Ted Karkus: And in one year. I was offered $20 to $25 million for it; 18 months later, I sold it for $50 million. The only difference was we had to develop a little more. We fine tuned the marketing a little bit more, built it a little more, and then we got twice as much. So these are decisions I'm working on every day. But again, I'm the largest shareholder in the company; every decision I make is what's best for the shareholders. They always come first.

Ted Karkus: We'll see how it plays out. I was offered 20 to $25 million for it. 18 months later, I sold it for $50 million. The only difference was we had to develop it a little more.

Speaker Change: I was offered 20 to 25 million dollars for it. 18 months later, I sold it for 50 million dollars.

Ted Karkus: We fine-tuned the marketing a little bit more, built it a little more, and then we got twice as much. So these are decisions I'm working on every day. But again, I'm the largest shareholder in the company. Every decision I make is what's best for the shareholders. They always come first. Okay. Finally, so that's enough about Beefmore.

Speaker Change: The only difference was we had to develop a little more we fine-tuned the marketing a little bit more built it a little more And then we got twice as much so these are decisions. I'm working on every day, but again I'm the largest shareholder in the company every decision. I make is what's best for the shareholders. They always come first, okay?

Unknown Executive: The only difference was we had to develop a little more. We fine tuned the marketing a little bit more, built it a little more, and then we got twice as much. So these are decisions I'm working on every day. But again, I'm the largest shareholder in the company, every decision I make is what's best for the shareholders. They always come first. Okay. Finally, so that's enough on Beatsmore. We talked about FHC.

Ted Karkus: Okay.

Ted Karkus: We talked about FHC. I do want to just touch on Equivir a little bit and then we'll get to questions. Interesting how I'm about to wrap up, and it worked out to exactly about 30 minutes.

Ted Karkus: Finally, so that's enough on Beatsmore. We talked about FHC. I do want to just touch on Equivier a little bit, and then we'll get questions.

Speaker Change: Finally, so that's enough on Beastmort, we talked about FHC, I do want to just touch on Equivir a little bit and then we'll get to questions.

Ted Karkus: Interesting how I'm about to wrap up, and it worked out to exactly about 30 minutes. I didn't plan that. Okay, Equivier, we're in the final stages. There's over 300; our goal was 300 patients, 250 patient groups. Understand, this is a study where there were two arms to it. One was a prophylactic study where you take the product once a day to avoid getting sick. The other 150 patients was on people who were sick, giving them the products, seeing if it worked therapeutically, got phenomenal results in both arms. Understand, these are people getting colds, lose, and COVID.

Unknown Executive: I do want to just touch on Equivier a little bit and then we'll get questions. Interesting how I'm about to wrap up and it worked out to exactly about 30 minutes. I didn't plan that. Okay, Equivier, we're in the final stages. There's over 300, our goal was 300 patients, 250 patient groups. Understand, this is a study where there were two arms to it. One was a prophylactic study where you take the product once a day to avoid getting sick.

Speaker Change: Interesting how I'm about to wrap up and it worked out to exactly about 30 minutes. I didn't plan that.

Ted Karkus: I didn't plan that. Okay, Aquavir, we're in the final stages. We have over 300, you know; our goal was 300 patients; we have 250 patient groups. Understand, this is a study where there were two arms to it. One was a prophylactic study where you take the product once a day to avoid getting sick. The other 150 patients were on people who were sick, giving them the product, and seeing if it worked therapeutically. I got phenomenal results in both arms.

Speaker Change: Okay, Equivir, we're in the final stages.

Speaker Change: over 300, you know, our goal was 300 patients.

Speaker Change: We have 250 patient groups.

Speaker Change: Understand this is a study where there were two arms to it. One was a prophylactic study where you take the product once a day to avoid getting sick. The other 150 patients...

Unknown Executive: The other 150 patients was on people who were sick, giving them the products, seeing if it worked therapeutically, got phenomenal results in both arms. Understand, these are people getting colds, lose, and COVID. Now, we will not be able to make COVID claims on our packaging, but I believe we will be able to publish our study results and point to them. And so potential consumers can read the studies for themselves. It's very compelling.

Ted Karkus: Understand these are people getting colds, flu, and COVID. Now, we will not be able to make COVID claims on our packaging, but I believe we will be able to publish our study results and point to them. And so potential consumers can read the studies for themselves. It's very compelling.

Speaker Change: was on people who are sick, giving them the products, seeing if it worked therapeutically. Got phenomenal results in both arms. Understand these are people getting colds, flus, and COVID.

Ted Karkus: Now, we will not be able to make COVID claims on our packaging, but I believe we will be able to publish our study results and point to them. And so potential consumers can read the studies for themselves. It's very compelling. The retailers are very interested in this product. So we already have this whole infrastructure in place in selling to retail stores. I'm excited to get started, but the beauty of our initiative with Nebula Genomics and building that whole social media platform is we're going to build that for Equivier too. So what's interesting is that our whole Nebula team is actually just as excited about developing a range of dietary supplements on the social media platform.

Speaker Change: Now, we will not be able to make COVID claims on our packaging, but I believe we will be able to publish our study results and point to them, and so potential consumers can read the studies for themselves. It's very compelling. The retailers are very interested in this product.

Ted Karkus: The retailers are very interested in this product, so we already have this whole infrastructure in place for selling to retail stores. I'm excited to get started.

Unknown Executive: The retailers are very interested in this product. So we already have this whole infrastructure in place in selling to retail stores. I'm excited to get started, but the beauty of our initiative with nebula genomics and building that whole social media platform is we're going to build that for Equivier too. So what's interesting is that our whole nebula team is actually just as excited about developing a range of dietary supplements on the social media platform.

Speaker Change: So, we already have this whole infrastructure in place in selling to retail stores. I'm excited to get started. But the beauty of our initiative with Nebula Genomics and building that whole social media platform is we're going to build that for Equivir too. What's interesting is our whole Nebula...

Ted Karkus: But the beauty of our initiative with Nebula Genomics and building that whole social media platform is we're going to build that for Equivir too. What's interesting is our whole Nebula team is actually just as excited about developing a range of dietary supplements on the social media platform. It could be a very exciting business. And it's something where we already have most of the pieces. We also, by the way, years ago, when we developed the TK Supplements line of products, we developed Legends XL, Triple Edge, and Super Prostaflow.

Speaker Change: team is actually just as excited about developing

Speaker Change: a range of dietary supplements.

Ted Karkus: Could be a very exciting business, and it's something where we already have most of the pieces. We also, by the way, years ago, when we developed the TK supplements line of products that we developed Legends, Excel and Triple Edge and Superprosta Flow and Legends, Excel has been stores, we never really focused on the other two. But legends, Excel plus triple Edge, if you take them combined, it's actually a great pre-workout product. Legends, Excel is a great product by itself. So, but now we already have the credibility from legends, Excel being in Walgreens, CBS, and other stores.

Speaker Change: on the social media platform.

Speaker Change: Could be a very exciting business and it's something where we already have most of the pieces We also by the way years ago when we developed the TK supplements line of products that we developed legends XL and triple edge and super pasta flow

Unknown Executive: Could be a very exciting business, and it's something where we already have most of the pieces. We also, by the way, years ago, when we developed the TK supplements line of products that we developed legends, Excel and triple Edge and superprosta flow and legends, Excel has been stores, we never really focused on the other two. But legends, Excel plus triple Edge, if you take them combined, it's actually a great pre-workout product legends, Excel is a great product by itself.

Ted Karkus: And Legends XL is in stores. We never really focused on the other two. But Legends XL plus Triple Edge, if you take them combined, it's actually a great pre-workout product. Legends XL is a great product by itself.

Speaker Change: and Legends XL is in stores. We never really focus on the other two, but Legends XL plus Triple Edge, if you take them combined, it's actually a great pre-workout product.

Ted Karkus: But now we already have the credibility from Legends XL being in Walgreens, CVS, and other stores, and now we're going to leverage it online. We could potentially build out a whole line of products from that. I don't want to talk more about that. Now I will in the Q&A, if you're interested. I think I fairly covered everything that I wanted to say.

Speaker Change: LegendsXL is a great product by itself, but now we already have the credibility from LegendsXL being in Walgreens, CVS, and other stores.

Ted Karkus: And now we're going to leverage it online. We could potentially build out a whole line of products from that. I don't want to talk more about that.

Unknown Executive: So, but now we already have the credibility from legends, Excel being in Walgreens, CBS and other stores. And now we're going to leverage it online. We could potentially build out a whole line of products from that. I don't want to talk more about that. Now I will in the Q&A if you're interested. I think I fairly covered everything that I wanted to say. So my partner, Noella, I handed it back over to you for the Q&A.

Speaker Change: and now we're going to leverage it online. We could potentially build out a whole line of products from that. I don't want to talk more about that. Now I will in the Q&A, if you're interested. I think I fairly covered everything that I wanted to say.

Ted Karkus: Now I will in the Q&A if you're interested.

Ted Karkus: I think I fairly covered everything that I wanted to say.

Noella: So, my partner, Noella, I hand it back over to you for the Q&A. Thank you very much, Ted, for the presentation. So now we will begin the Q&A. Your first question is: Please provide some detail about Forward Health Care and why you chose them. The website has a 2021 copyright, and it looks older than that and provides very little detail about the company, about what the company actually does, and about who its customers are.

Unknown Executive: So my partner, Noella, I handed it back over to you for the Q&A.

Speaker Change: So my partner Noella, I hand it back over to you for the Q&A.

Unknown Executive: Thank you very much, Ted, for the presentation.

Unknown Executive: So now we will begin the Q&A.

Unknown Executive: Your first question is, please provide some detail about Forward Healthcare and why you choose them.

Noella: Thank you very much, Ted, for the presentation. So now we will begin the Q&A.

Unknown Executive: Thank you very much, Ted, for the presentation. So now we will begin the Q&A. Your first question is, please provide some detail about forward healthcare and why you choose them. The website has a 2021 copyright and it looks older than that and provides very little detail about the company, about what the company actually does and who customers are. Thanks. Thank you. Okay, sure. So, excellent question. I think I covered a lot of this in the presentation.

Noella: Your first question is...

Ted Karkus: The website has a 2021 copyright, and it looks older than that and provides very little detail about the company, about what the company actually does and who customers are. Thanks. Thank you. Okay, sure. So, excellent question. I think I covered a lot of this in the presentation. But I will just touch on it again. The three consultants we're working with have different skill sets, but they are skill sets cover every aspect of not only commercializing our B Smart Test, but developing the demand for it. And I think they said there are three components to this.

Speaker Change: Please provide some detail about Forward Healthcare and why you choose them. The website has a 2021 copyright and it looks older than that and provides very little detail about what the company actually does and who customers are. Thank you.

Ted Karkus: Thank you. Okay, sure. So, um, excellent question. I think I covered a lot of this in the presentation, but I will just touch on it again.

Ted Karkus: The three consultants we're working with have different skill sets, but their skill sets cover every aspect of not only commercializing our B-Smart test but developing the demand for it. And as I said, there are three components to this. So one is an expert with FDA and CPT codes and insurance companies. And another is an expert with the Physician Network. And another is an expert in tying it all together.

Speaker Change: Okay, sure.

Speaker Change: Excellent question. I think I covered a lot of this in the presentation, but I will just touch on it again. The three consultants we're working with have different skill sets.

Unknown Executive: But I will just touch on it again. The three consultants we're working with have different skill sets, but they are skill sets cover every aspect of not only commercializing our B Smart Test, but developing the demand for it. And I think they said there are three components to this. So, one is an expert with FDA and CPT codes and insurance companies and another is an expert with the physician network and another is an expert in tying it all together.

Unknown Executive: And these gentlemen are really excited to work with us and they're working with us regularly now almost on a daily basis. And we are going, I believe we now have the partners we need. And what they're also going to do in addition to everything I just said, they're going to bring in the key opinion leaders. So much of this is, and I don't want to say it's political because we have a fantastic test.

Speaker Change: But their skill sets cover every aspect of not only commercializing our B-Smart test,

Ted Karkus: So, one is an expert with FDA and CPT codes and insurance companies, and another is an expert with the physician network, and another is an expert in tying it all together. And these gentlemen are really excited to work with us, and they're working with us regularly now, almost on a daily basis. And we are going; I believe we now have the partners we need. And what they're also going to do, in addition to everything I just said, they're going to bring in the key opinion leaders. So much of this is, and I don't want to say it's political because we have a fantastic test.

Speaker Change: But developing the demand for it and as I said, there are three components to this

Speaker Change: So, one is an expert with FDA and CPT codes and insurance companies, and another is an expert with the Physician Network, and another is an expert in tying it all together. And these gentlemen are really excited.

Ted Karkus: And these gentlemen are really excited to work with us. And they're working with us regularly now, almost on a daily basis. And we're going, I believe we now have the partners we need, and what they're also going to do, in addition to everything I just said, they're going to bring in the key opinion leaders. So much of this is, and I don't want to say it's political because we have a fantastic test.

Speaker Change: to work with us and they're working with us regularly now almost on a daily basis and We're going I believe We now have the partners we need and what they're also going to do in addition to everything I just said they're going to bring in the key opinion leaders so much of this

Ted Karkus: At the end of the day, you have to have a fantastic test. But once you have a fantastic test, then the question is, how do you get the GIs, the physicians, to sign on and order it? How do you get the insurance companies to reimburse it?

Ted Karkus: The other day, you have to have a fantastic test. But once you have a fantastic test, then the question is, how do you get the GI's, the physicians, to sign on and order it? How do you get the insurance companies to reimburse it? You know, there's another cancer test, and I don't want to say it by name. You know, they have like a 30 or 40 million dollar market cap because they did sort of a fast track approach to cash based testing, but they're having trouble getting the insurance companies to sign on. They still have a 30-40 million market cap.

Speaker Change: is, and I don't want to say it's political, because we have a fantastic test. At the end of the day, you have to have a fantastic test. But once you have a fantastic test, then the question is,

Unknown Executive: The other day, you have to have a fantastic test. But once you have a fantastic test, then the question is, how do you get the GI's, the physicians to sign on and order it? How do you get the insurance companies to reimburse it? You know, there's another cancer test, and I don't want to say it by name, you know, they have like a 30 or 40 million dollar market cap because they they did sort of a fast track approach to cash based testing, but they're having trouble getting the insurance companies to sign on.

Speaker Change: How do you get...

Speaker Change: the GIs, the physicians, to sign on and order it? How do you get the insurance companies to reimburse it?

Ted Karkus: you know there's another cancer test and I don't want to say it by name you know they have like a 30 or 40 million dollar market cap because they they did sort of a fast track approach to cash based testing but they're having trouble getting the insurance companies to sign on they still have a 30 40 million market cap and so we all think that they did it the wrong way now if FHC had been working with them the whole time they might have taken a different approach instead of a 30 40 million dollar market cap they might have a three or four billion dollar market cap like garden health which is a company that FHC did work on so we want to do this the right way if I want to get this out quickly I could do an IPO of our be smart esophageal cancer test and have a in a year have a 30 or $40 million market cap for it potentially. I want it to have a billion-dollar worth. That's, that's the goal. It can happen. We'll see. I know that we have a great set, all the rest, we have to figure out and I want to do it the right way.

Speaker Change: You know, there's another cancer test and I don't want to say it by name

Unknown Executive: They still have a 30 40 million market cap. And so we all think that they did it the wrong way. Now, if a FHC had been working with them the whole time, they might have taken a different approach instead of a 30 40 million dollar market cap. They might have a three or four billion dollar market cap, like Gordon Health, which is a company that FHC did work on. So we want to do this the right way.

Speaker Change: You know...

Speaker Change: They have like a 30 or 40 million dollar market cap.

Speaker Change: because they did sort of a fast track approach to cast-based testing, but they're having trouble getting the insurance companies.

Ted Karkus: And so we all think that they did it the wrong way. Now, if a FHC had been working with them the whole time, they might have taken a different approach instead of a 30-40 million dollar market cap. They might have a three or four billion dollar market cap, like Gordon Health, which is a company that FHC did work on. So we want to do this the right way. If I want to get this out quickly, I could do an IPO of our Beast Martisophage, you'll cancer test and have a year or have a 30 or 40 million dollar market cap for it potentially.

Speaker Change: to sign on, they still have a 30, 40 million mark gap, and so we all think that they did it the wrong way.

Speaker Change: Now, if FHC had been working with them the whole time, they might have taken a different approach. Instead of a $30, $40 million markup, they might have a $3 or $4 billion markup like Garden Health, which is a company that FHC did work on. So we want to do this the right way. If I want to get this out quickly, I could do an IPO.

Unknown Executive: If I want to get this out quickly, I could do an IPO of our Beast Martisophage, you'll cancer test and have a year or have a 30 or 40 million dollar market cap for it potentially. I want it to have a billion dollar market cap. That's the goal is going to happen. We'll see. I know that we have a great test. All the rest, we have to figure out and I want to do it the right way and we have time to do it the right way.

Speaker Change: of our Be Smart, Estophageal Cancer test and in a year have a 30 or 40 million dollar market cap for it potentially. I want it to have a billion dollar market cap. That's the goal. It's gonna happen, we'll see. I know that we have a great test.

Ted Karkus: I want it to have a billion-dollar market cap. That's the goal. It's going to happen. We'll see. I know that we have a great test. All the rest, we have to figure out, and I want to do it the right way, and we have time to do it the right way. Listen, I'm the first in line for, you know, immediate gratification when it comes to buying stocks and that kind of thing. But as a CEO of our company, I got to build the value of the company over time, and we have, you know, bumps along the way, and we had a bump here.

Ted Karkus: And we have time to do it the right way. Listen, I'm the first in line for, you know, immediate gratification when it comes to buying stocks and that kind of thing. But as the CEO of our company, I got to build the value of the company over time. And we have, you know, bumps along the way. We had a bump here, obviously, we had a bump, you know, with the stock price. We had a bump; I don't have control over the stock market itself. The stock market for micro cap stocks has been in a bear market for four years, but it tried to show a little life earlier this year.

Speaker Change: All the rest we have to figure out, and I want to do it the right way, and we have time to do it the right way.

Unknown Executive: Listen, I'm the first in line for, you know, immediate gratification when it comes to buying stocks and that kind of thing. But as a CEO of our company, I got to build the value of the company over time and we have, you know, bumps along the way and we had a bump here. Obviously we had a bump, you know, with the stock price. We have a bump. I don't have control over the stock market itself stock market for microcaps stocks has been in a bear market for four years.

Speaker Change: I'm the first in line for, you know, immediate gratification when it comes to buying stocks and that kind of thing, but as the CEO of our company

Speaker Change: I've got to build the value of the company over time, and we have.

Ted Karkus: Obviously, we had a bump, you know, with the stock price. We have a bump. I don't have control over the stock market itself. Stock market for microcaps stocks has been in a bear market for four years. It tried to show a little life earlier in this year, and then we just had a, what I think is a selling climax. I think, well, honestly all the microcaps biotech stocks are probably bottom and we're washed out a couple of weeks ago and the Dow is not a thousand points. So I'm looking forward to how do we build the value in the company going forward and be smart by itself.

Speaker Change: you know, bumps along the way, we had a bump here, obviously we had a bump.

Speaker Change: you know, with the stock price.

Speaker Change: We have a bump. I don't have control over the stock market itself. The stock market for micro-cap stocks...

Ted Karkus: And then we just had a selling climax. I think, well, honestly, all the micro cap biotech stocks have probably bottomed and were washed out a couple of weeks ago when the Dow was at 1000 points. So I'm looking forward to how we build the value of the company going forward and be smart by itself. Forget everything else I've talked about. Be smart. You know, I might be able to not only retire, but I might be able to start writing my own book.

Speaker Change: has been in a bear market for four years, it tried to show a little life earlier in this year and then we just had a what I think is a selling climax. I think well honestly all the microcaps

Unknown Executive: It tried to show a little life earlier in this year and then we just had a, what I think is a selling climax. I think, well, honestly all the microcaps biotech stocks are probably bottom and we're washed out a couple of weeks ago and the Dow is not a thousand points. So I'm looking forward to how do we build the value in the company going forward and be smart by itself. Forget everything else I talked about.

Speaker Change: Biotech stocks have probably bottomed and were washed out a couple of weeks ago when the Dow was at 1,000 points. So I'm looking forward to how do we build the value in the company going forward and be smart by itself. Forget everything else I've talked about.

Unknown Executive: Forget everything else I talked about. Be smart, you know, I might be able to not only retire, I might be able to start writing my own books on what we're going to do with Be smart. So anyway, great question. Thank you. Next one, please.

Speaker Change: Be smart, you know, I might be able to not only retire, I might be able to start writing my own books on what we're going to do with Be Smart. So anyway, great question. Thank you. Next one, please, Noelle.

Unknown Executive: Be smart, you know, I might be able to not only retire, I might be able to start writing my own books on what we're going to do with be smart. So anyway, great question. Thank you. Next one, please. Great, the next question for you is, my family has a history of a sausage yield cancer. Why can I obtain the B-Smart test? Well, you know, that makes me feel bad. I'm really sorry.

Ted Karkus: What we're going to do is be smart. So anyway, great question. Thank you. Next one, please. Right, the next question for you is, my family has a history of a soft geotanser. One, can I obtain the Beast Smart Test? Well, you know, that makes me feel bad. I'm really sorry. esophageal cancer, you know, and this happens, you know. I talked about this test. You know, I don't know why it makes me feel so sick.

Unknown Executive: Great, the next question for you is, my family has a history of a sausage yield cancer. Why can I obtain the B-Smart test? Well, you know, that makes me feel bad. I'm really sorry. A sausage yield cancer, you know, and this happens, you know. I talk about this test, you know; I don't know why it makes me cure up. I talk about this test, you know, and sometimes I'll talk to an institutional investor. I can't tell you; it surprises me every time, but like one out of every several people has had to deal with a sausage yield cancer.

Noelle: Great, the next question for you is, my family has a history of esophageal cancer, when can I obtain the B-SMART test?

Unknown Executive: A sausage yield cancer, you know, and this happens, you know, I talk about this test, you know, I don't know why it makes me cure up. I talk about this test, you know, and sometimes I'll talk to an institutional investor. I can't tell you, it surprises me every time, but like one out of every several people has had to deal with a sausage yield cancer. You know, and I, you know, when I talk about it, I say X percentage, you know, once you're diagnosed, 18 and 90 percent of people diagnosed die.

Speaker Change: Well, you know, that makes me feel bad. I'm really sorry. Esophageal cancer, you know, and this happens, you know, I talk about this stuff.

Ted Karkus: I talked about this test, you know, and sometimes I'll talk to an institutional investor. I can't tell you how surprised I am every time but like one out of every several people has had to deal with esophageal cancer. You know, and I, when I talk about it, I say x percentage. You know, once you're diagnosed, 80 to 90% of people diagnosed die. I say that, and then somebody says to me, you know, the family member has esophageal cancer. And I'm like, I almost feel sorry that I said that statistic. It's really a terrible statistic.

Speaker Change: I don't know why it makes me tear up. I talk about this test, you know, and sometimes I'll talk to an institutional investor. I can't tell you...

Speaker Change: It surprises me every time, but like one out of every several people.

Ted Karkus: You know, and I, you know, when I talk about it, I say X percentage, you know, once you're diagnosed, 18 and 90 percent of people diagnosed die. I say that, and then somebody says to me, you know, the family member has a sausage of cancer, and I'm like, and I must feel sorry that I said that statistic. It's really a terrible statistic. So, you know, but it's more common than you then you realize. So, as far as our test is concerned, it's a great question, and it's complicated because the FDA is making it more complicated.

Speaker Change: has had to deal with esophageal cancer, you know, and I you know when I talk about it I say X percentage, you know, once you're diagnosed 80 to 90 percent of people diagnosed die I say that and then somebody says to me, you know The family member has esophageal cancer and I'm like I almost feel sorry that I said that statistic It's really a terrible statistic

Unknown Executive: I say that, and then somebody says to me, you know, the family member has a sausage of cancer, and I'm like, and I must feel sorry that I said that statistic. It's really a terrible statistic. So, you know, but it's more common than you then you realize. So as far as our test is concerned, it's a great question, and it's complicated because the FDA is making it more complicated. It's possible. We could provide this as a cash-based test, but apparently I also don't want to set a precedent with doing it as a cash-based test, and then having issues with the insurance companies, and I don't know all of the politics involved.

Ted Karkus: So, you know, but it's more common than you realize. So as far as our test is concerned, it's a great question. And it's complicated because the FDA is making it more complicated. It's possible. We could provide this as a cash-based test, but I also don't want to set a precedent with doing it as a cash-based test and then having issues with the insurance companies.

Speaker Change: So, you know, but it's more common than you than you realize. So as far as our test is concerned, it's a great question.

Ted Karkus: And I don't know all of the politics involved. But honestly, if somebody actually wanted to get a test and reach out to our company, we can certainly do the test, but that's different from commercialization. So, I'm working with the FAC consultants right now. I don't have all the answers just yet. I don't want to be rushed and put into a box. That's exactly how we're going to roll this out. And again, there's a difference between CPT codes, which might give us the right answer. Um, um, to get reimbursed by insurance. And it's very different from actually getting reimbursed by insurance.

Unknown Executive: So, but honestly, if somebody actually wanted to get a test and reach out to our company, we can certainly do the test, but that's different from commercialization. So I'm working with the FAC consultants right now. I don't have all the answers today. I don't want to be rushed and put into a box that's exactly how we're going to roll this out. And again, there's a difference between CPT codes, which might give us the right to get reimbursed by insurance.

Ted Karkus: It's possible. We could provide this as a cash-based test, but apparently I also don't want to set a precedent with doing it as a cash-based test, and then having issues with the insurance companies, and I don't know all of the politics involved. So, but honestly, if somebody actually wanted to get a test and reach out to our company, we can certainly do the test, but that's different from commercialization. So I'm working with the FAC Consultants right now. I don't have all the answers today. I don't want to be rushed and put into a box. That's exactly how we're going to roll this out.

Speaker Change: And it's complicated because the FDA is making it more complicated. It's possible we could provide this as a cash-based test, but apparently I also don't want to set a precedent with doing it as a cash-based test and then having issues with the insurance companies. And I don't know all of the politics.

Speaker Change: involved.

Speaker Change: So, but honestly, if somebody actually wanted to get a test and reach out to our company, we can certainly...

Speaker Change: do the test.

Speaker Change: but that's different from commercialization. So I'm working with the FHC consultants right now. I don't have all the answers today. I don't want to be rushed and put into a box as to exactly how we're going to roll this out. And again, there's a difference between CPT codes, which might give us the rights.

Ted Karkus: And again, there's a difference between CPT codes, which might give us the right to get reimbursed by insurance. It's very different from actually getting reimbursed by insurance. And I said, as I said, there's another cancer testing company that's public. It's got a $30, $40 million mark out. I don't know if they're going anywhere. I also, again, their test is pre-endoscopy. So again, it would only help our COGS if they became more successful. I don't know if they will. I hope that answers your question. I'm sorry. I don't have a better answer today. But certainly, if somebody really wanted to be tested, we certainly could.

Ted Karkus: And I said, as I said, there's another cancer testing company that's public. It's got a $30, $40 million mark out. I don't know if they're going anywhere. And also, again, their test is pre-endoscopy.

Speaker Change: Um

Speaker Change: to get reimbursed by insurance is very different from actually getting reimbursed by insurance.

Ted Karkus: So again, it would only help our clogs if they became less successful. I don't know if they will. I hope that answers your question. I'm sorry.

Unknown Executive: It's very different from actually getting reimbursed by insurance. And I said, as I said, there's another cancer testing company that's public. It's got a $30, $40 million mark out. I don't know if they're going anywhere. I also, again, their test is pre-endoscopy. So again, it would only help our cogs if they became more successful. I don't know if they will. I hope that answers your question. I'm sorry. I don't have a better answer today.

Speaker Change: and I said as I said there's another cancer testing company that's public it's got a 30 40 million dollar market I don't know that they're going anywhere I also again their test is pre endoscopy so again it would only help our cause if they became more successful I don't know that they will I hope that answers your question I'm sorry I don't have a better answer today

Ted Karkus: I don't have a better answer today, but certainly, if somebody really wanted to be tested today by us, we certainly could. We're capable of doing this. Thank you for elaborating, Ted. The next question is, Please elaborate on your recent SEC filing about the CrowdStrike incident preventing Prophase from filing its Q2 results on time. Is this an ongoing issue for the company? I don't even understand why somebody would ask that question.

Speaker Change: But certainly, if somebody really wanted to be tested today by us, we certainly could. We're capable of doing the test.

Ted Karkus: We're capable of doing the test.

Unknown Executive: But certainly, if somebody really wanted to be tested, we certainly could. We're capable of doing the test. Thank you for elaborating 10. The next question is, please elaborate on your recent SEC filing about the CrowdStrike incident preventing prophase from filing its Q2 results on time. Is this an ongoing issue for the company? I don't even understand why somebody would ask a question. We just reported results because we reported four days later which we're allowed to do.

Unknown Executive: Thank you for elaborating 10.

Ted Karkus: The next question is, please elaborate on your recent SEC filing about the CrowdStrike incident preventing Prophase from filing its Q2 results on time. Is this an ongoing issue for the company? I don't even understand why somebody would ask a question. We just reported results because we reported four days later, which we're allowed to do. Honestly, that question is just a waste of time. No, there's no ongoing issue. We just reported results. So you're asking about an issue that isn't an issue since we just reported results. So I don't even understand the question. I don't care about the CrowdStrike.

Speaker Change: Thank you for elaborating, Ken. The next question is...

Unknown Executive: Honestly, that question is just a waste of time. No, there's no ongoing issue. We just reported results. So you're asking about an issue that isn't an issue since we just reported results. So I don't even understand the question. I don't care about the CrowdStrike. That affected a lot of companies, but we reported our results today, which we're allowed to do. So what's the next question in the world? Thank you. The next question is the two parts.

Speaker Change: Please elaborate on your recent SEC filing about the CrowdStrike incident preventing ProPhase from filing its Q2 results on time. Is this an ongoing issue for the company?

Ted Karkus: We just reported results because we reported them four days later, which we're allowed to do. Honestly, that question is just a waste of time. No, there's no ongoing issue.

Speaker Change: I don't even understand why somebody would ask a question. We just reported results because we reported them four days later, which we're allowed to do. Honestly, that question is just a waste of time. No, there's no ongoing issue. We just reported results. So you're asking about an issue that isn't an issue since we just reported results.

Ted Karkus: We just reported results, so you're asking about an issue that isn't an issue since we just reported results. So I don't even understand the question. I don't care about the crowds, right?

Ted Karkus: That affected a lot of companies, but we reported our results today, which we're allowed to do. So what's the next question? No, thanks.

Unknown Executive: That affected a lot of companies, but we reported our results today, which we're allowed to do. So what's the next question in the world? Thank you.

Speaker Change: So, I don't even understand the question. I don't care about the crowd strike. You know, that affected a lot of companies, but we reported our results today, which we're allowed to do. So, what's the next question, Noel? Thank you.

Ted Karkus: The next question is the two parts. The first part is, this prophase continued to have an investment in lantern forma. And if so, what is the thinking about it? Long term hold or potential source of cash in the short term? And if farm laws is generating cash in growing, why look to sell this when profitable assets? That's right. I don't want to hear anymore about Lantern. That's a question I don't really want to touch on. It sounds like a lantern shareholder or a lantern executive asking the question. So thank you for trying to leverage our shareholder conference call to talk about Lantern.

Ted Karkus: The next question is two parts. The first part is, does Prophase continue to have an investment in Lantern Pharma? And if so, what is their thinking about it?

Noel: The next question is a two-part. The first part is, does Profase continue to have an investment in Lantern Pharma, and if so, what is the thinking about it? Long-term hold or potential source of cash in the short-term? And, if PharmaLawz is generating cash and growing, why look to sell this one profitable asset?

Unknown Executive: The first part is, this prophase continued to have an investment in lantern forma. And if so, what is the thinking about it? Long term hold or potential source of cash in the short term? And if farm laws is generating cash in growing, why look to sell this when profitable assets? That's right. I don't want to hear anymore about lantern. That's a question I don't really want to touch on. It sounds like a lantern shareholder or a lantern executive asking the question.

Ted Karkus: Long-term hold or potential source of cash in the short term? And if PharmaLaws is generating cash and growing, why look to sell this one profitable asset? For, That's right. I don't want to hear any more about Lantern.

Ted Karkus: That's a question I don't really want to touch on, but it sounds like a Lantern shareholder or an Lantern executive is asking the question. So thank you for trying to leverage our shareholder conference call to talk about Lantern. I'm not going to comment further on it during this call, but thank you. Thank you, Ted, for the response. The next question is... What is happening at the diagnostics lab if there are no more COVID tests? We're not doing COVID testing.

Speaker Change: His soul.

Speaker Change: That's right. I don't want to hear any more about Lantern. That's a question I don't really want to touch on. It sounds like a Lantern shareholder or a Lantern executive asking the question. So thank you for trying to leverage our shareholder conference call to talk about Lantern. I'm not going to comment further on it in this call, but thank you.

Unknown Executive: I'm not going to comment further on it in the school, but thank you. Thank you.

Unknown Executive: So thank you for trying to leverage our shareholder conference call to talk about lantern. I'm not going to comment further on it in the school, but thank you. Thank you. The next question is what is happening at the diagnostic lab if there's no more COVID testing? We're not doing code testing. We built out, we converted our COVID lab into a world class genomics lab, and now we're looking to ramp up our our nebula genomics business, which we rebranded DNA complete, and we look to fill up our lab with business from DNA complete DNA complete by itself.

Ted Karkus: The next question is what is happening at the diagnostic lab if there's no more COVID testing? We're not doing code testing. We built out, we converted our COVID lab into a world class genomics lab, and now we're looking to ramp up our Nebula Genomics business, which we rebranded DNA Complete, and we look to fill up our lab with business from DNA Complete by itself. Nebula Genomics DNA complete without the lab is a fantastic business. I'm really excited about it. The lab is expensive to operate. So we're going to build up the business, and we'll see where it goes.

Speaker Change: Thank you, Chad, for the response. The next question is...

Speaker Change: What is happening at the diagnostics lab if there's no more COVID testing?

Ted Karkus: We built out, and converted our COVID lab into a world-class genomics lab. And now we're looking to ramp up our Nebula Genomics business, which we've rebranded DNA Complete, and we look to fill up our lab with business from DNA Complete by itself. DNA Complete without the lab is a fantastic business. I'm really excited about it.

Speaker Change: We're not doing COVID testing. We built out, we converted our COVID lab into a world-class genomics lab and now we're looking to ramp up

Speaker Change: our Nebula Genomics business, which we've rebranded DNA complete.

Speaker Change: and we look to fill up our lab with business from DNA complete. DNA complete by itself

Speaker Change: You know, Nebula Genomics DNA Complete without the lab is a fantastic business. I'm really excited about it. The lab is expensive to operate, so we're going to build up the business.

Unknown Executive: Nebula genomics DNA complete without the lab is a fantastic business. I'm really excited about it. The lab is expensive to operate. So we're going to build up the business and we'll see where it goes. So, but I think the real value of the company, I mean, there is a value to the lab because we built it up with expensive equipment. It's a high quality lab. We could probably sell it. Maybe we will sell it.

Ted Karkus: The lab is expensive to operate, so we're going to build up the business, and we'll see where it goes. But I think the real value of the company is the lab because we built it up with expensive equipment as a high-quality lab. We could probably sell it. Maybe we will sell it. I don't want to get into strategy for the future, employees, and all those kinds of things.

Ted Karkus: So, but I think the real value of the company, I mean, there is a value to the lab because we built it up with expensive equipment. It's a high quality lab. We could probably sell it. Maybe we will sell it. I don't want to get into strategy in the future, employees, and all those kinds of things. But our new business model, which we're going to start ramping up right away, is going to leverage that lab. So, but as far as COVID testing, we don't do COVID testing; we moved away from that a long time ago.

Speaker Change: We'll see where it goes.

Speaker Change: I think the real value of the company, I mean there is a value to the lab because we built it out with expensive equipment, it's a high quality lab, we could probably sell it.

Ted Karkus: But our new business model, which we're going to start ramping up right away, is going to leverage that lab. But as far as COVID testing is concerned, we don't do COVID testing; we moved away from that a long time ago. And so to be clear, there are companies of the history of transitioning, as times change, we don't, we aren't stagnant, there are plenty of COVID companies, you know, COVID lab companies just went out of business when COVID ended.

Speaker Change: Maybe we will sell it. I don't want to get into, you know, strategy in the future, employees and all those kinds of things, but our new business model, which we're going to start ramping up right away, is going to leverage that lab.

Unknown Executive: I don't want to get into strategy in the future employees and all those kinds of things. But our new business model, which we're going to start ramping up right away, is going to leverage that lab. So, but as far as COVID testing, we don't do COVID testing where we we moved away from that long time ago. And so to be clear, our company out the history of transitioning. As times change, we don't we aren't stagnant.

Ted Karkus: And so, to be clear, our company out the history of transitioning. As times change, we don't we aren't stagnant. They're plenty of COVID company, you know, COVID lab companies just went out of business when COVID. All right, we had to call these brands. We sold it, kept the manufacturing facility. We're now potentially going to sell the manufacturing facility for just as much as we sold the cold these brand for. We got into COVID testing, made a ton of money in COVID. We then use that money to buy these other businesses and these other science and technology assets.

Speaker Change: So, but as far as COVID testing, we don't do COVID testing anymore. We moved away from that a long time ago. And so to be clear, our company has a history of transitioning.

Ted Karkus: All right, we had the Coldease brand, we sold it, kept the manufacturing facility, and we're now potentially going to sell the manufacturing facility for just as much as we sold the Coldease brand for. We got into COVID testing, and made a ton of money on COVID. We then use that money to buy other businesses and these other science and technology assets. That's what we're developing now. One was Equivir, which I think has been a fantastic product.

Speaker Change: As times change...

Speaker Change: We don't, we aren't stagnant. There are plenty of COVID company, you know, COVID lab companies that just went out of business when COVID ended. All right. We had the ColdEase brand, we sold it, kept the manufacturing facility. We're now potentially going to sell the manufacturing facility for just as much as we sold the ColdEase brand for. We got into COVID testing, made a ton of money in COVID. We then used that money to buy these other business and these other science and technology assets. That's what we're developing now. One was Equivir.

Unknown Executive: They're plenty of COVID company, you know, COVID lab companies just went out of business when COVID. All right, we had to call these brand. We sold it kept the manufacturing facility. We're now potentially going to sell the manufacturing facility for just as much as we sold the cold these brand for. We got into COVID testing made a ton of money in COVID. We then use that money to buy these other business and these other science and technology assets.

Ted Karkus: That's what we're developing now. One was Aquavir, which I think is a fantastic product. Equivir by itself could make our company hugely valuable. Equivir, which I'm not even focused on, let alone we acquired that bill. The genomics which we're building out, be smart, associated with your cancer tests, which we acquired and we're building out. So we use the COVID, do we use the cold these sell to one focus on building formulas and to it gave us the ability to get into the COVID testing business. We then think equity does a phenomenal job of raising capital force back when we got into the COVID test.

Ted Karkus: Equivir by itself could make our company hugely valuable. Equivir, which I'm not even focused on, let alone we acquired Nebula Genomics, which we're building out, Be Smart, Assize, and Vigil Cancer Test, which we acquired and we're building out. So we use... The COVID cell? Did we use the COVID cell?

Unknown Executive: That's what we're developing now. One was aquavir, which I think is fantastic product. Equivir by itself could make our company hugely valuable. Equivir, which I'm not even focused on, let alone we acquired that bill. The genomics which we're building out, be smart, associated with your cancer tests, which we acquired and we're building out. So we use the COVID, do we use the cold these sell to one focus on building formulas and to it gave us the ability to get into the COVID testing business.

Speaker Change: which I think is a fantastic product. Equivira by itself could make our company hugely valuable. Equivira, which I'm not even focused on, let alone we acquired Nebula Genomics, which we're building out, Be Smart Assess the Geo Cancer Test, which we acquired and we're building out. So we used...

Ted Karkus: to one, focus on building pharma labs, and two, it gave us the ability to get into the COVID testing business. Think Equity did a phenomenal job of raising capital for us back when we got into COVID testing. We built that out. We then, with that filled out with the money that we made, we then found new assets to develop.

Speaker Change: We use the Colby cell.

Speaker Change: to, one, focus on building farm laws, and, and two...

Speaker Change: it gave us the ability to get into the COVID testing business. We then think equity did a phenomenal job of raising capital for us back when we got into the COVID testing. We built that out. We then with that filled out with the money that we made, we then found new assets to develop. And those are the new assets that are going to develop and be very valuable over time.

Ted Karkus: We built that out. We then, with that, build out with the money that we made. We then found new assets developed, and those are the new assets that are going to develop me very valuable over time. So that's what we do. I'm an entrepreneur. We go with the times that everything is successful, but my track record of success in developing new companies has been incredibly high for an incredibly long period of time.

Unknown Executive: We then think equity does phenomenal job of raising capital force back when we got into the COVID test. We built that out. We then with that build out with the money that we made, we then found new assets developed and those are the new assets that are going to develop me very valuable over time. So that's what we do. I'm an entrepreneur. We go with the times that everything is successful, but my track record of success in developing new companies has been incredibly high for an incredibly long period of time.

Ted Karkus: And those are the new assets that are going to develop and be very valuable over time. So that's what we do. I'm an entrepreneur. We go with the times. Not everything is successful, but my track record of success in developing new companies has been incredibly high for an incredibly long period of time. Thank you for that. Next question, please. Thank you, Ted. The next question is, It looks like there are now only two options for Nebula, deep and ultra deep. Did you discontinue the standard option? And what was the rationale?

Speaker Change: So that's what we do. I'm an entrepreneur. We go with the times. Not everything is successful, but my track record of success in developing new companies has been incredibly high for an incredibly long period of time.

Unknown Executive: Thank you for that.

Unknown Executive: Next question, please. Thank you, Ted. The next question is it looks like there are not only two options for Nebula, deep and ultra deep. Did you discontinue the standard option, and what was the rationale? Are you no longer offering lifetime membership? No, so we've done a complete overall. We're rolling that out, excuse me, very shortly. That will all be clarified in about a week. Wait until you see the new websites, the new rebranding, all of that. You know, we're having a quarterly call today. It would have been nice if we had a quarterly call after, you know, the rebranding launched.

Speaker Change: Thank you for that. Next question please.

Unknown Executive: Thank you for that. Next question, please. Thank you, Ted. The next question is it looks like there are not only two options for Nebula, deep and ultra deep. Did you discontinue the standard option and what was the rationale? Are you no longer offering lifetime membership? No, so we've done a complete overall. We're rolling that out, excuse me, very shortly. That will all be clarified in about a week, wait until you see the new websites, the new rebranding, all of that.

Speaker Change: Thank you, Ted. The next question is...

Speaker Change: It looks like there are now only two options for Nebula, Deep and Ultra Deep. Did you discontinue the standard option and what was the rationale? Are you no longer offering lifetime membership?

Ted Karkus: Are you no longer offering lifetime membership? No, so we've done a complete overhaul. We're rolling that out, excuse me, very shortly. That'll all be clarified in about a week. Wait until you see the new websites, the new rebranding, all that, you know, we're having the quarterly call today. It would have been nice. I'll provide updates in the coming weeks.

Speaker Change: No, so we've done a complete overhaul. We're rolling that out, excuse me, very shortly. That'll all be clarified in about a week. Wait until you see the new websites, the new rebranding, all that. You know, we're having the quarterly call today. It would have been nice.

Unknown Executive: You know, we're having a quarterly call today. It would have been nice if we had a quarterly call after, you know, the rebranding launched. You know, the timing didn't work out perfectly, but I'll provide updates in the coming weeks when this all launched and I'll answer those questions. We have a variety of great products. We have 100x, we have a 30x, we have a 1x, and we have a DNA expand. The DNA expand is taking the ancestry test and giving you more information on the ancestry test that you've already taken elsewhere.

Ted Karkus: You know, the timing didn't work out perfectly, but I'll provide updates in the coming weeks when this all launches, and I'll answer those questions. We have a variety of great products. We have 100x; we have a 30x; we have a 1x; and we have a DNA expand. The DNA expand is taking the ancestry test and giving you more information on the ancestry test that you've already taken elsewhere. And then the 1x, which we think is a phenomenal product, is incredibly low price, and it's still a thousand to five thousand times more data than you get from an ancestry test.

Speaker Change: If we had a quarterly call after, you know, the rebranding launched, you know, the timing didn't work out perfectly, but I'll provide updates in the coming weeks when this all launches and I'll answer those questions. We have a variety of great products. We have 100X.

Ted Karkus: We have a variety of great products. We have 100X, we have a 30X, we have a 1X, and we have a DNA expand. The DNA expand is taking the ancestry test and giving you more information on the ancestry test that you've already taken elsewhere.

Unknown Executive: And then the 1x, which we think is a phenomenal product, is incredibly low price, and it's still a thousand to five thousand times more data than you get from an ancestry test. And yet it's price similar to an ancestry test. We think it's going to be a huge product, but we'll see when we roll it out. So we'll see once we roll out with our new social media platform and all the people we're working with, and we're going to be bringing in influencers, there's a lot of places we can go.

Speaker Change: We have a 30X, we have a 1X, and we have a DNA expand. The DNA expand...

Speaker Change: is taking the Ancestry test and giving you more information on the Ancestry test that you've already taken elsewhere. And then the One X, which we think is a phenomenal product, is incredibly low priced.

Ted Karkus: And then the 1X, which we think is a phenomenal product, is incredibly low priced, and it's still a thousand to five thousand times more data than you get from an ancestry test. And yet, its price is similar to an ancestry test. We think we're going to be a huge product, but we'll see when we roll it out. So we'll see once we roll out with our new social media platform and all the people we're working with. And we're going to be bringing in influencers. There are a lot of places we can go.

Ted Karkus: And yet its price is similar to an ancestry test. We think it's going to be a huge product, but we'll see when we roll it out. So we'll see once we roll out with our new social media platform and all the people we're working with, and we're going to be bringing in influencers. There's a lot of places we can go. This is going to be very exciting. So you'll see, but the answer to your question is this will all be made clear very soon. Thank you for that response, Ted.

Speaker Change: And it's still 1,000 to 5,000 times more data than you get from an Ancestry test. And yet it's priced similar to an Ancestry test. We think it's going to be a huge product, but we'll see when we roll it out. So we'll see once we roll out with our new social media platform and all the people we're working with. And we're going to be bringing in influencers. There's a lot of places we can go. This is going to be very exciting.

Ted Karkus: This is going to be very exciting. So you'll see. But the answer to your question is, this will all be made clear versus. Thank you for that response, Ted.

Unknown Executive: This is going to be very exciting. So you'll see, but the answer to your question is this will all be made clear very soon. Thank you for that response, Ted. Next, one will be the second line at the factory become operational and its potential production is spoken for. Yeah, so we have excellent question. We have several customers, some very large that are very interested, and we're just in negotiations now. The margins are different between one's very large lozens brand and a dozen smaller brands.

Speaker Change: So you'll see, but the answer to your question is this will all be made clear very soon.

Ted Karkus: Next, when will the second line at the factory become operational, and its potential production spoken for? Yeah, so we have... Excellent question we have several customers, some very large, that are very interested, and we're just in negotiations. The margins are different between one very large license brand and a dozen smaller brands.

Ted Karkus: Next, one will be the second line at the factory become operational, and its potential production is spoken for. Yeah, so we have an excellent question. We have several customers, some very large that are very interested, and we're just in negotiations now. The margins are different between one's very large lozens brand and a dozen smaller brands. So we have our line one, we have ridiculously high margins for manufacturing company. That, by the way, is very attractive to potential acquired. We have really high margins. It's really cool business for line one, and that's all spoken for. And we're running that capacity.

Ted Karkus: Thank you for that response, Ted. Next, when will the second line at the factory become operational and is potential production spoken for?

Speaker Change: Yeah, so we have, excellent question, we have

Speaker Change: several customers, some very large, that are very interested.

Speaker Change: Bye. Bye. Bye.

Speaker Change: and we're just in negotiations now.

Speaker Change: The margins are different between one very large license brand and a dozen smaller brands. So we have, on our line one, we have ridiculously high margins for manufacturing companies.

Ted Karkus: So on our line one, we have ridiculously high margins for manufacturing. That, by the way, is very attractive to potential acquirers. We have really high margins. It's a really cool business for line one. And that's all spoken for.

Unknown Executive: So we have our line one, we have ridiculously high margins for manufacturing company. That by the way is very attractive to potential acquired. We have really high margins. It's really cool business for line one, and that's all spoken for. And we're running that capacity. In fact, we're looking to hire people right now as quickly as possible. For line two, we're in negotiations right now. So we'll see where they go. We just, the timing was perfect.

Ted Karkus: And we're running at that capacity. In fact, we're looking to hire people right now, as quickly as possible, for line two. We're in negotiations right now, so we'll see where they go. We just think the timing was perfect.

Speaker Change: That, by the way, is very attractive to a potential acquirer. We have really high margins. It's a really cool business for Line 1, and that's what it's spoken for, and we're running that capacity. In fact, we're looking to hire people right now as quickly as possible. For Line 2...

Ted Karkus: In fact, we're looking to hire people right now as quickly as possible. For line two, we're in negotiations right now. So we'll see where they go. We just, the timing was perfect. One of the largest lozenge brands in the world we just reconnected with, and they indicated an interest in taking our entire capacity to line two. But then understand it becomes a negotiation. Do we want to sell the entire capacity to line two? And by the way, I might get enough down payment if we do it that way. But the margins on that business are going to be significantly less than if we sell to a dozen small customers.

Ted Karkus: One of the largest lots of brands in the world. We just reconnected, and they indicated an interest in taking our entire capacity to line up with, but then you understand it becomes a negotiation. Do we want to sell the entire capacity line to them, and by the way, I might get a good enough price down payment if we do it that way. But the margins on that business are going to be significant. Definitely less than if we sold to, you know, a dozen small customers. The problem with the dozen small customers is that they come and go; some are successful, some aren't.

Speaker Change: We're in negotiations right now. So we'll see where they go. We just, the timing was perfect.

Speaker Change: a one of the largest license brands in the world we just reconnected with and they indicated an interest in taking our entire capacity for line two, but then understand it becomes a negotiation.

Unknown Executive: One of the largest lozens brands in the world we just reconnected with, and they indicated an interest in taking our entire capacity to line two. But then understand it becomes a negotiation, do we want to sell the entire capacity to line two? And by the way, I might get enough down payment if we do it that way. But the margins on that business are going to be significantly less than if we sell to a dozen small customers.

Speaker Change: Do we want to sell the entire capacity line, too? And by the way, I might get enough down payment if we do it that way.

Ted Karkus: And more importantly, with the smaller customers, you run a line for a couple of days, and then you're done with their production, and then you have to clean the whole line and start all over again a couple of days later with the new Lawson's brand.

Speaker Change: But the margins on that business are going to be significantly less than if we sell to, you know, a dozen small customers. The problem with a dozen small customers is that they come and go. Some are successful, some aren't.

Ted Karkus: The problem with the dozen small customers is that they come and go. Some are successful, some aren't, and more importantly, with the smaller customers, you run a line for a couple of days and then you're done with their production, and then you have to clean the whole line and start all over again a couple of days later with a new lozens brand, and then the same thing over and over again. It's a lot more work; it's a lot more tedious, but we charge them a lot more. So there are trade-offs, and we just have to see how it comes.

Unknown Executive: The problem with the dozen small customers that they come and go, they, some are successful, some aren't, and more importantly, with the smaller customers, you run a line for a couple of days and then you're done with their production and then you have to clean the whole line and start all over again, a couple of days later with a new lozens brand, and then the same thing over and over again. It's a lot more work, it's a lot more tedious, but we charge them a lot more.

Speaker Change: More importantly with the smaller customers you run a line for a couple of days And then you're done with their production, and then you have to clean the whole line and start all over again a couple days later with a new

Ted Karkus: And then the same thing over and over again. It's a lot more work. It's a lot more tedious, but we charge them a lot more. So there are trade-offs, and we just have to see how it goes. So the second line we're looking to install this year, but I don't know the exact month.

Speaker Change: Lawson's brand, and then the same thing over and over again. It's a lot more work. It's a lot more tedious.

Ted Karkus: So the second line, we're looking to install it this year. I don't know the exact month. So we'll see. We're playing this a lot. But again, our estimates for the numbers I have provided for formalized for the next 12 months do not include any contribution at all from lying to, so that would just be out enough. So and so the point also is beyond lying to we can we potentially we have room in our current plan for a third line. And so understand a potential acquire. They're not only interested in your current business. You're interested in whether or not you can expand on whether the demands are.

Speaker Change: but we charge them a lot more.

Speaker Change: So, there are trade-offs and we just have to see how it goes.

Unknown Executive: So there are trade-offs and we just have to see how it comes. So the second line, we're looking to install it this year. I don't know the exact month. So we'll see. We're playing this a lot. But again, Our estimates for the numbers I have provided for formalized for the next 12 months do not include any contribution at all from lying to so that would just be out enough. So and so the point also is beyond lying to we can we potentially we have room in our current plan for a third line.

Speaker Change: So, the second line, we're looking to install it this year. I don't know the exact month. So, we'll see. We're playing this off. But again...

Ted Karkus: So we'll see. We're playing this a lot. But again, our estimates for the numbers I have provided for formalized, for the next 12 months, do not include any contribution at all from lying. So that would just be out and on. So, and so the point also is, beyond lying to, we can add, potentially, we have room in our current plan for a third line. And so understand a potential acquisition. They're not only interested in your current business. You're interested in whether or not you can expand on whether the demands there are.

Ted Karkus: We definitely have room to explain. We already have world-class consultants who figured out the whole point, which, however long it took, took six or nine months.

Speaker Change: Our estimates for the numbers I have provided

Speaker Change: for PharmaLabs for the next 12 months. Do not include any contribution at all from line two.

Speaker Change: So that would just be added on.

Speaker Change: So, and so the point also is,

Speaker Change: beyond line 2, we have room in our current plant for a third line.

Speaker Change: and so understand a potential acquirer.

Unknown Executive: And so understand a potential acquire. They're not only interested in your current business. You're interested in whether or not you can expand on whether the demands are. We definitely have room to explain we already have we have world class consultants who figured out the whole plan that however long that took six or nine months. So we built out the whole plan and we already have line two which was ordered a year and a half ago that's that's coming.

Ted Karkus: We definitely have room to explain we already have we have world class consultants who figured out the whole plan that however long that took six or nine months. So we built out the whole plan, and we already have line two, which was ordered a year and a half ago, that's coming. I mean, you know very soon, and we have the plans for line three, and we have demand all over the place because a critically important component of this is the fact it's several things that we have going for one is our reliability. We are one of the most reliable. We have the best reputation for manufacturing logic number two. We are FDA approved; there are very few.

Speaker Change: They're not only interested in your current business, they're interested in whether or not you can expand and whether the demands are. We definitely have room to expand. We already have world-class consultants who figured out the whole plan.

Ted Karkus: So we built out the whole plan, and we already have the line lying to which was ordered a year and a half ago that's coming, you know, very soon. And we have the plans for line three.

Speaker Change: However long that took, six or nine months, so we built out the whole plan and we already have line two Which was ordered a year and a half ago. That's coming, you know, very soon and we have the plans for line three

Unknown Executive: I mean, you know very soon and we have the plans for line three and we have demand all over the place because a critically important component of this is the fact it's several things that we have going for one is our reliability. We are one of the most reliable we have the best reputation for manufacturing logic number two we are FDA approved there are very few. Loss and manufacturers in the world that are FDA approved and have capacity and are reliable but we don't know any.

Speaker Change: and we have demand all over the place because a critically important component of this is the fact it's several things we have going for us. One, it's our reliability.

Ted Karkus: And we have demand all over the place because a critically important component of this is the fact we have several things that we have going for us. One, it's our reliability. We are one of the most reliable. We have the best reputation for manufacturing licenses. Number two, we are FDA approved. There are very few, the largest manufacturers in the world, that are FDA approved and Half Capacity Endor Reliable, but we don't know any.

Speaker Change: We are one of the most reliable, we have the best reputation for manufacturing licenses. Number two, we are FDA approved. There are very few...

Ted Karkus: Loss and manufacturers in the world that are FDA approved and have capacity and are reliable but we don't know any. All right. And three were based in the United States. So anyone selling licenses into the United States would strongly prefer to work with a manufacturer in the United States, especially since there is a threat of tariffs coming. Now, I don't know who's going to win the election, but. If Trump runs the election, I think to probably a tariffs are very high. I don't know if he doesn't what happens, but if Trump wins, everybody's going to be an attack to want to give us a business like not even a question.

Speaker Change: licensed manufacturers in the world that are FDA-approved.

Speaker Change: and have capacity and are reliable, but we don't know what any.

Ted Karkus: All right. Um, and three were based in the United States. So anyone selling lodgings into the United States would strongly prefer to work with a manufacturer in the United States, especially since there is a threat of tariffs coming. Now I don't know who's going to win the election, but I'm hoping Trump wins the election. I think the probability of tariffs is very high. I don't I don't know if he doesn't what happens.

Unknown Executive: All right. And three were based in the United States. So anyone selling licenses into the United States would strongly prefer to work with a manufacturer in the United States, especially since there is a threat of tariffs coming. Now, I don't know who's going to win the election but. If Trump runs the election, I think to probably a tariffs are very high. I don't know if he doesn't what happens, but if Trump wins, everybody's going to be an attack to want to give us a business like not even a question.

Speaker Change: All right, and three, we're based in the United States. So anyone selling lozenges into the United States would strongly prefer to work with a manufacturer in the United States, especially since there is a threat of tariffs coming.

Speaker Change: Now, I don't know who's going to win the election, but...

Ted Karkus: But if Trump wins, everybody's going to be in a panic to want to give us business, like not even a question. So, regardless, the demand is there. We're going to a conference in a couple of months.

Speaker Change: If Trump wins the election, I think the probability of tariffs are very high. I don't know if he doesn't, what happens. But if Trump wins, everybody's going to be in a panic.

Ted Karkus: So, but regardless, the demand is there. We're going to conference in a couple of months, and we already know there's a dozen new brands there that want to give us the business. So this is just a booming business. It's a hidden asset of the company at the moment, but it won't be for more than a quarter of two.

Speaker Change: to want to give us a business, like not even a question. So, but regardless, the demand is there. We're going to a conference in a couple of months, and we already know there's a dozen new brands there that want to give us their business.

Unknown Executive: So but regardless, the demand is there we're going to we're going to conference in a couple of months and we already know there's a dozen new brands there that want to give us the business. So this is just a booming business. It's a hidden asset of the company at the moment, but it won't be for more than a quarter of two. Thank you for that response, Ted.

Ted Karkus: And we already know there are a dozen new brands there that want to give us their business. So this is just a booming business. It's a hidden asset of the company at the moment, but it won't be for more than a quarter of a year. Thank you for that response, Ted. Your next question is for some Hunter Diamond from Diamond Equity. Can you please discuss the marketing approach for Be Smart If Approved?

Speaker Change: So this is just a booming business. It's a hidden asset of the company at the moment, but it won't be for more than a quarter or two.

Ted Karkus: Thank you for that response, Ted.

Hunter Diamond: Your next question is for Hunter Hunt some hunter diamond from Diamond Equity. And you please discuss the marketing approach for B Smart if approved. Would you anticipate further partnerships to assist? Yeah, so we can go in a couple of different directions. We have a. This is going to be a high-class problem to have, and I don't want to misspeak. But we've been waiting, and I've been waiting for these final statistical results to bring them to one of the largest cancer diagnostic companies in the world. I'm pretty sure we could partner with them. But again, look out three years from today and look backwards.

Speaker Change: Thank you for that response, Ted. Your next question is from Hunter Diamond from Diamond Equity. Can you please discuss the marketing approach for Be Smart if Approved? Would you anticipate further partnerships to assist?

Ted Karkus: Your next question is for hunter hunt some hunter diamond from diamond equity.

Ted Karkus: Would you anticipate further partnerships to assist? Yeah, so we can go in a couple of different directions. We have a, There's going to be a high-class problem to have, and I don't want to mispeak. Um, but we've been waiting for these final statistical results to bring them to one of the largest cancer diagnostic companies in the world. I'm pretty sure we could partner with them. But again, look out three years from today and look backwards.

Ted Karkus: And you please discuss the marketing approach for B smart if approved. Would you anticipate further partnerships to assist? Yeah, so we can go in a couple of different directions. We have a. This is going to be a high class problem to have and I don't want to misspeak. But we've been waiting and I've been waiting for these final statistical results to bring them to one of the largest cancer diagnostic companies in the world.

Speaker Change: Yes, so we can go in a couple of different directions. We have a...

Speaker Change: This is going to be a high class problem to have and I don't want to misspeak.

Speaker Change: Um, bye.

Speaker Change: We've been waiting. I've been...

Hunter Diamond: waiting for these final statistical results to bring them to one of the largest cancer diagnostic companies in the world. I'm pretty sure we could partner with them.

Ted Karkus: I'm pretty sure we could partner with them. But again, look out three years from today and look backwards. Would you rather I do a deal where we get some money upfront and a royalty? Or what are three years from now? Are these more topical cancer tests really as worth a big amount of money? We're not going to be at a bear market in microcaps forever. And our Beastmart Cancer Test, I don't know how many times I can say it's a multi-billion dollar target market, as far as I'm concerned, no real competition.

Hunter Diamond: But again...

Ted Karkus: Would you rather I do a deal where, you know, we get some money up front and a royalty? Or what if three years from now? Our Beastmore esophageal cancer test really is worth a large amount of money.

Hunter Diamond: Look out three years from today.

Ted Karkus: Would you rather I do a deal where we get some money upfront and a royalty? Or what are three years from now? Are these more topical cancer tests really as worth a big amount of money? We're not going to be at a bear market in microcaps forever. And our Beastmart Cancer Test, I don't know how many times I can say it's a multi-billion dollar target market; as far as I'm concerned, no real competition. So I feel like it's inevitable. I really feel like it's inevitable. It's not a guarantee; again, four-looking statements. I can't guarantee this.

Hunter Diamond: and look backwards. Would you rather I do a deal where we get some money upfront and a royalty?

Hunter Diamond: Or, what if three years from now?

Speaker Change: Our Beastmore esophageal cancer test really is worth a big amount of money.

Ted Karkus: We're not going to be in a bear market in micro caps forever. And our cancer test. You know, I don't know how many times I can say it's a multi-billion dollar target market with, as far as I'm concerned, no, no real competition. So I feel like it's inevitable. I really feel like it's inevitable.

Speaker Change: We're not going to be in a bear market in microcaps forever, and our BeSmart cancer test, you know, I don't know how many times I can say it, it's a multi-billion dollar target market with, as far as I'm concerned, no real competition.

Ted Karkus: It's not a guarantee. Again, these are forward-looking statements. I can't guarantee this. It may not happen.

Ted Karkus: But I don't I just, in my heart, I believe this can be a really, really, big test and a really big deal. And so what shareholders should really be thinking about is, let's formalize, give us all the cash in the world to build these other businesses, sit back and see where we are in two or three years, and it could be an oh my god situation. Um, while we're growing, these other businesses are going to be very valuable. Look Nebula, I think this could be worth a lot of money in a year. Um, I really do.

Speaker Change: So I feel like it's inevitable. I really feel like it's inevitable. It's not a guarantee. Again, forward-looking statements. I can't guarantee this. It may not happen. But I don't... I just... In my heart, I believe this is going to be really, really...

Ted Karkus: So I feel like it's inevitable. I really feel like it's inevitable. It's not a guarantee, again, four-looking statements. I can't guarantee this. It may not happen. But I don't, I just, in my heart, I believe this can be really, really big test, and a really big deal.

Ted Karkus: It may not happen. But I don't, I just, in my heart, I believe this can be really, really big test, and a really big deal. And so what shareholders should really be thinking about is, let's self-farmilize, give us all the cats in the world, build these other businesses, sit back, and see where we are in two or three years, and it could be an "oh my god" situation. While we're growing these other businesses, it can be very valuable. Look, Nebula, I think that's one way I can slice and dice this, and we'll just have to see.

Ted Karkus: And so what shareholders should really be thinking about is, let's self-farmilize, give us all the cats in the world, build these other businesses, sit back, and see where we are in two or three years, and it could be an oh my god situation. While we're growing these other businesses, it can be very valuable. Look, Nebula, I think that's one way I can slice and dice this, and we'll just have to see.

Speaker Change: Big test and a really big deal and so what shareholders should really be thinking about

Speaker Change: is, let's self-formalize, gives us all the cash in the world, build these other businesses, sit back.

Speaker Change: and see where we are in two or three years and it could be an oh my god situation.

Speaker Change: While we're growing these issues, the business is going to be very valuable. Look, Nebula, I think that's going to be worth a lot of money in here.

Ted Karkus: So when I and, uh, you know, there's a lot of different ways I can slice and dice this, and we'll just have to see. But the answer is, yes, there's one possibility that we could partner with a very large current cancer testing company that has the entire sales force and distribution in place. But, on the other hand, with FHC behind us.

Speaker Change #100: I really do. So there's a lot of different ways I can slice and dice this and we'll just have to see, but the answer is yes, there's one possibility that we could partner with a very large current cancer testing company that has the entire sales force and distribution in place.

Ted Karkus: But the answer is, yes, there's one possibility that we could partner with a very large current cancer testing company that has the entire Salesforce and distribution in place. But on the other hand, with FHC behind us, if we get all these various networks that we need between the physician network and the insurance company on board, and we can roll this out, look, just our director at Optum, if they sign up for our test, we've got the insurance companies, they sign up for a test, it's a home run, what I want to do with the old big company for, you know, they'll just take it.

Ted Karkus: But the answer is, yes, there's one possibility that we could partner with a very large current cancer testing company that has the entire Salesforce and distribution in place. But on the other hand, with FHC behind us, if we get all these various networks that we need between the physician network and the insurance company on board, and we can roll this out, look, just our director at Optum, if they sign up for our test, we've got the insurance companies, they sign up for a test, it's a home run, what I want to do with the old big company for, you know, they'll just take it.

Ted Karkus: If we get all these various networks that we need between the physician network and the insurance companies on board, we can roll this out. Look, just our director at Optum, if they sign up for a test, we get the insurance companies on board, they sign up for a test, it's a home run. We don't want to do a deal with a big company for it. You know, they'll just take it.

Speaker Change #100: But on the other hand,

Speaker Change #100: with FHC behind us, if we get all these various networks

Speaker Change #101: that we need between the physician networks and the insurance companies on board and we can roll us out. Look, just our director at Optum.

Speaker Change #101: If they sign up for our test, we get the insurance companies, they sign up for a test, it's a home run. We don't want to do a deal with a big company for it. You know, they'll just take it.

Ted Karkus: Um, so we'll see. There are various ways we can go with this. Well, it's still relatively early in the game.

Ted Karkus: So we'll see; there's various ways we can go with this. It's still relatively early on in the game. But we're not that far away from this having an intrinsic value that the market, that the market would appreciate. And then that gives us options down the road. I'm not allowed to talk about IPOs and precondition the market and things like that. But the thing is IPOs and spinouts and dividend to shareholders, things like that will have those, I believe, will have those opportunities next year. In addition to the alternative, which is selling to a big company.

Speaker Change #101: So we'll see, there's various ways we can go with this.

Ted Karkus: So we'll see, there's various ways we can go with this. It's still relatively early on in the game. But we're not that far away from this having an intrinsic value that the market, that the market would appreciate. And then that gives us options down the road. I'm not allowed to talk about IPOs and precondition the market and things like that. But the thing is IPOs and spinouts and dividend to shareholders, things like that will have those, I believe will have those opportunities next year.

Speaker Change #101: still relatively early on in the game.

Speaker Change #101: But we're not that far away from this having an intrinsic value that the market would appreciate. And then that gives us options down the road. I'm not allowed to talk about IPOs and preconditioning the market and things like that. But the thing is...

Ted Karkus: Um, but we're not that far away from this having an intrinsic value that the market would appreciate. And then that gives us options down the road. I'm not allowed to talk about IPOs and precondition the market and things like that.

Speaker Change #101: IPOs and spin outs and dividend shareholders, things like that, I believe we'll have those opportunities next year.

Ted Karkus: But the thing is, IPOs and spin-offs and dividends to shareholders, things like that. We'll have those. I believe we'll have those opportunities next year, in addition to the alternative, which is selling to a big company. But do I really want to sell to a big company for tens of millions of dollars in royalties? You know, I don't know what the numbers would be versus if this really is a billion-dollar opportunity. Thank you, Newell. Thank you, Ted. The next question is, please address the adequacy of your liquidity until revenues ramp up. Boy, that's a great question.

Speaker Change #101: in addition to

Ted Karkus: But I really want to sell to a big company for tens of millions of dollars in royalty. You know, I don't know what the numbers would be versus if this really is a billion dollar opportunity. Thank you, Nuala.

Ted Karkus: In addition to the alternative, which is selling to a big company. But I really want to sell to a big company for tens of millions of dollars in royalty. You know, I don't know what the numbers would be, versus if this really is a billion dollar opportunity. Thank you, Nuala. Thank you, Tess.

Speaker Change #101: The alternative, which is selling to a big company. But, do I really want to sell to a big company for tens of millions of dollars in royalty? You know, I don't know what the numbers would be. Versus if this really is a billion dollar opportunity.

Ted Karkus: Thank you, Tess.

Ted Karkus: The next question is, please address the adequacy of your liquidity until revenues ramp up. Boy, that's a great question. We have money flowing in. If you notice our network and capital, I don't remember it as I've talked about my ad; we reported on the front page. We have a significant network and capital. We have a significant accounts receivable, dollars low in on a regular basis. We're also about to also formalize; is about to now start contributing in the third quarter. It didn't end in the second quarter. We're very disappointed in the second quarter. In the third quarter, they're going to contribute in a significant way.

Speaker Change #101: Thank you, Noelle.

Speaker Change #101: Thank you, Ted. The next question is, please trust the adequacy of your liquidity until revenues ramp up.

Ted Karkus: We have money flowing in. If you notice our networking capital, I don't remember it off the top of my head, we reported on the front page. We have significant networking capital, we have significant accounts receivable, dollars flow in on a regular basis. We're also about to formalize is about to now start contributing in the third quarter, and then in the second quarter, very disappointed in the second quarter. In the third quarter, they're going to contribute in a significant way. So just formalizing alone, that switch brings our monthly burn down.

Speaker Change #102: Boy that's a great question!

Ted Karkus: The next question is, please address the adequacy of your liquidity until revenues ramp up. Boy, that's a great question. We have money flowing in. If you notice our network and capital, I don't remember it as I've talked about my ad, we reported on the front page. We have a significant network and capital. We have a significant accounts receivable, dollars low in on a regular basis. We're also about to also formalize, is about to now start contributing in the third quarter.

Speaker Change #103: We have money flowing in. If you notice our net working capital, I don't remember it off the top of my head, we reported on the front page. We have a significant net working capital. We have a significant accounts receivable. Dollars flow in on a regular basis.

Speaker Change #103: We're also about to, also PharmaLabs is about to now start contributing in the third quarter.

Speaker Change #104: And then in the second quarter, very disappointed in the second quarter, in the third quarter, they're going to contribute in a significant way. So just formalize alone that switch.

Ted Karkus: It didn't end in the second quarter. We're very disappointed in the second quarter. In the third quarter, they're going to contribute in a significant way. So just formalize alone. That switch brings our burn, our monthly burn down. We also then have some initiatives, a couple of them are very, very big initiatives on our accounts receivable. That could surprise me at any time. I just don't have a dependent answer because you're dealing with the government.

Ted Karkus: So just formalize alone. That switch brings our burn, our monthly burn down. We also then have some initiatives; a couple of them are very, very big initiatives on our accounts receivable. That could surprise me at any time. I just don't have a dependent answer because you're dealing with the government. The government moves slowly. We're highly optimistic that the government moves slowly. At some point, we're going to get a surprise. It gets a very large block of money. and then from the era, of course, with the statistical alternatives that we're pursuing with formalized, understand beside the sale, even if we were to sell it, that's not to say that, you know, somebody in private equity couldn't come along soon and say, buy a piece of it for discounts of what we're going to sell it for and taking a large black money.

Ted Karkus: We also have some initiatives, a couple of them are very, very big initiatives in our accounts receivable that could surprise me at any time. I just don't have a definitive answer because you're dealing with the government, and government moves slowly. We're highly optimistic that the government will move slowly. So at some point, we're going to get a surprise against, you know, a very large block of money. And then from there, of course, with the strategic alternatives that we're pursuing with the farm laws.

Speaker Change #104: brings our monthly burn down. We also then have some initiatives, a couple of them are very, very big initiatives.

Speaker Change #104: at our accounts receivable. That could surprise me at any time. I just don't have a definitive answer because you're dealing with the government and government moves slowly. We're highly optimistic, but the government moves slowly. So at some point we're going to get a surprise. It's, you know, a very large block of money.

Ted Karkus: The government moves slowly. We're highly optimistic that the government moves slowly. At some point, we're going to get a surprise. It gets a very large block of money, and then from the era, of course, with the statistical alternatives that we're pursuing with formalized, understand beside the sale, even if we were to sell it, that's not to say that, you know, somebody in private equity couldn't come along soon and say, buy a piece of it for discounts of what we're going to sell it for and taking a large black money.

Speaker Change #104: And then from there, of course, with the strategic alternatives that we're pursuing with pharma laws, understand beside the sale, even if we were to sell it, that's not to say that somebody in private equity couldn't come along.

Ted Karkus: Understand, besides the sale, even if we were to sell it, that's not to say that, you know, somebody in private equity couldn't come along soon and say, buy a piece of it for a discount to what we're going to sell it for and take a large block of money. So there are lots of different ways we can slice and dice this, and we'll just have to see. So right now, we're quoting a development state company. The market doesn't like development state companies.

Ted Karkus: So there are lots of different ways we can slice and dice this, and we'll just have to say, so right now we're quote a development state company; the market doesn't like development state company. I think the market is going to behave very differently at some point in the near future. Finally, I think we're going to get some interest rate cuts. We get we got a taste of the microcaps starting to bounce earlier in the year, and then they cracked again. At some point after four, you can bear market in the microcaps; microcaps are going to start up again.

Speaker Change #105: soon and say buy a piece of it for a discount to what we're going to sell it for and taking a large block money. So there are lots of different...

Ted Karkus: So there are lots of different ways we can slice and dice this and we'll just have to say, so right now we're quote a development state company, the market doesn't like development state company. I think the market is going to behave very differently at some point in the near future. Finally, I think we're going to get some interest rate cuts. We get we got a taste of the microcaps starting to bounce earlier in the year and then they cracked again. At some point after four, you can bear market in the microcaps, microcaps are going to start up again.

Speaker Change #105: We can slice and dice this and we'll just have to see so right now we're quote a development state company the market doesn't like development stake company, I think the market

Ted Karkus: I think the market is going to behave very differently at some point in the near future. Finally, I think we're going to get some interest rate cuts. We got a taste of microcaps starting to bounce earlier in the year, but then they cracked again.

Speaker Change #105: is going to is going to behave very differently at some point in the near future. Finally, I think we're going to get some interest rate cuts.

Ted Karkus: At some point, after four years of a bear market in microcaps, microcaps are going to start up again, so things could feel very, very differently in a few months, and we just have to get through the next six months. But we have so much underlying value in the company. You know, we'll just have to play.

Speaker Change #106: We got a taste of the microcaps starting to bounce earlier in the year and then they cracked again. At some point after four years of bear market in the microcaps, microcaps are going to start up again. So things could feel very, very differently in a few months, and we just have to get through the next six months. But we have so much underlying value in the company.

Ted Karkus: So things could feel very, very differently in a few months, and we just have to get through the next six months. But we have so much underlying and value in the company. You know, we'll just have to play. It's a dynamic situation. I don't have one definitive answer for you. I hope that answers your question, but that's the best answer I can give you. We just, you know, we're on a daily basis. Money is flowing in, and we're moving accordingly. I know that we have another black money coming in tomorrow's matter of fact. So we have ample cash right now and, you know, we'll just play by year over time.

Ted Karkus: So things could feel very, very differently in a few months and we just have to get through the next six months. But we have so much underlying and value in the company. You know, we'll just have to play. It's a dynamic situation. I don't have one definitive answer for you. I hope that answers your question, but that's the best answer I can give you. We just, you know, we're on a daily basis.

Ted Karkus: It's a dynamic situation. I don't have one definitive answer for you. I hope that answers your question, but that's the best answer I can give you.

Speaker Change #107: You know, we'll just have to play. It's a dynamic situation. I don't have one definitive answer for it.

Ted Karkus: We just, you know, you know. We're on a daily basis. Money is flowing in, and we're moving accordingly. I know that we have another block of money coming in tomorrow, as a matter of fact.

Speaker Change #107: I hope that answers your question.

Speaker Change #108: But that's the best answer I can give you. We're on a daily basis. Money is flowing in, and we're moving accordingly. I know that we have another black money coming in tomorrow's matter of fact. So we have ample cash right now, and we'll just play for a year over time. Obviously, once we sell formulas.

Ted Karkus: Money is flowing in and we're moving accordingly. I know that we have another black money coming in tomorrow's matter of fact. So we have ample cash right now and, you know, we'll just play by year over time.

Ted Karkus: So we have ample cash right now and, you know, we'll just play it by ear over time. Obviously, once we sell Farm last, game over, we're a completely different company, and but also, at that point, these other businesses I'm talking about, Nebula, will be ramping up more, and hopefully Equivir will have rolled out by then.

Ted Karkus: Obviously, once we sell Paramelize, you know, game armor will be a completely different company at that point. But also, at that point, these other businesses I'm talking about, you know, Nebula will be ramping up more. Hopefully, Epivir will have rolled out by then and, you know, we'll be talking very differently than we're talking today anyway. But having said all that again, Paramelize is kicking in right now. This quarter, you can count on it. The numbers are real. The business is real. We're at capacity. We're over capacity. We're looking to hire people today to work at Paramelize on the business that we have at high margin business as a very profitable business.

Ted Karkus: Obviously, once we sell Paramelize, you know, game armor will be completely different company at that point. But also, at that point, these other business I'm talking about, you know, Nebula will be ramping up more. Hopefully, Epivir will have rolled out by then and, you know, we'll be talking very differently than we're talking today anyway. But having said all that again, Paramelize is kicking in right now. This quarter, you can count on it.

Speaker Change #109: You know, Game Over were a completely different company at that point, but also at that point these other businesses I'm talking about, you know, Nebula will be ramping up more. Hopefully, Equivir will have rolled out by then and you know, we'll be talking very differently than we're talking today anyway.

Ted Karkus: And, you know, we'll be talking very differently than we are talking today. But having said all that again, PharmaLabs is kicking in right now, this quarter, you can count on it, the numbers are real, the business is real, we're at capacity, we're overcapacity. We're looking to hire people today to work at Farmalaz on the business that we have.

Speaker Change #109: But having said all that, again, PharmaLabs is kicking in right now, this quarter. You can count on it. The numbers are real. The business is real. We're at capacity.

Ted Karkus: The numbers are real. The business is real. We're at capacity. We're over capacity. We're looking to hire people today to work at Paramelize on the business that we have at high margin business as a very profitable business. And it's now for the first time contributing. I understand. Last year, we did about 9.3 million in Paramelize and it lost my, it was a drag. So just managed for the first time now in the current quarter.

Ted Karkus: And it's a high-margin business. It's a very profitable business. And it's now, for the first time, contributing. I understand last year we did about 9.3 million in Farmalaz, and it lost money. It was a drag.

Speaker Change #110: We're over capacity. We're looking to hire people today to work at Farmalaz on the business that we have and it's high margin business It's a very profitable business and it's now for the first time contributing. I understand last year We did about 9.3 million in Farmalaz and it lost money

Ted Karkus: And it's now for the first time contributing. I understand. Last year, we did about 9.3 million in Paramelize, and it lost my; it was a drag. So just managed for the first time now in the current quarter. All of a sudden, we're operating. Oh, and this is another point I want to tell you. Those estimates that I gave understand because of the seasonality of the business of that 14 to 16 million revenues, 5 plus million in earnings. If that's over the next 12 months, more of that is going to be in the first half of the year, the second half of the year, which means over the next two quarters, more than half of that should come in and revenues in earnings.

Ted Karkus: So just imagine for the first time now in the current quarter, all of a sudden we're operating. Oh, and there's another point I want to tell you. Those estimates that I gave understand because of the seasonality of the business, of that $14 to $16 million in revenues, $5 plus million in earnings, if that's over the next 12 months, more of that is going to be in the first half of the year, the second half of the year, which means over the next two quarters, more than half of that should come in and revenues in our, So that starts to add to the bottom line that takes a little pain away and the nebula genomics is we're going to with this complete rebranding we're not going to ramp that up that's going to now start to eat away at the overhead of our laboratory.

Speaker Change #110: it was a drag so just imagine for the first time now in the current quarter all of a sudden we're operating oh and there's another point i want to tell you

Ted Karkus: All of a sudden, we're operating. Oh, and this is another point I want to tell you. Those estimates that I gave understand because of the seasonality of the business of that 14 to 16 million revenues, 5 plus million in earnings. If that's over the next 12 months, more of that is going to be in the first half of the year, the second half of the year, which means over the next two quarter, more than half of that should come in and revenues in earnings. So that starts to add to the bottom line. That takes a little pain away.

Speaker Change #110: Those estimates that I gave, understand because of the seasonality of the business

Speaker Change #111: of that 14 to 16 million of revenues, 5 plus million in earnings, if that's over the next 12 months

Speaker Change #111: More of that is going to be in the first half of the year, the second half of the year, which means over the next two quarters more than half of that should come in and revenues in our

Ted Karkus: So that starts to add to the bottom line. That takes a little pain away. And the Nebula Genomics business, we're going to with this complete rebranding. We're not going to ramp that up. That's going to now start to eat away at the all red of our laboratory. So the numbers are going to start improving.

Speaker Change #111: So that starts to add to the bottom line. That takes a little of the pain away and the nebula genomics, because we're going to with this complete rebranding, we're not going to ramp that up. That's going to now start to eat away at the overhead of our laboratory. So the numbers are going to start improving.

Ted Karkus: And the Nebula genomics business, we're going to with this complete rebranding. We're not going to ramp that up. That's going to now start to eat away at the all red of our laboratory. So the numbers are going to start improving.

Ted Karkus: So the numbers are going to start improving. Next question, please. That was a good question. Thank you, Ted. We're coming up on your last two questions. The first one is, how far are we from having the family doctor request a DNA genomics test along with regular blood tests on a patient to determine if there is a risk of disease?

Ted Karkus: Next question, please. That was a good question. Thank you, Ted.

Unknown Executive: Next question, please. That was a good question. Thank you, Ted.

Unknown Executive: We're coming up on your last two questions. The first one is, how far away from having the family doctor request a DNA genomics test along with a regular blood test on a patient to determine if there is a risk of disease? It's a great question. That's where the world is going. That's the future of medicine. That's what we call personalized precision medicine. Again, it is a no-brainer that this is where medicine is going. I mean, just think about learning about your genetic genetic makeup. to tell you about disease that you're high risk of. You need to know that so then you can prevent yourself from getting those diseases.

Speaker Change #112: Next question please. That was a good question. Thank you, Ted. We're coming up on your last two questions. The first one is, how far are we from having the family doctor request a DNA genomics test along with regular blood tests on a patient to determine if there is a risk of disease?

Ted Karkus: We're coming up on your last two questions. The first one is, how far away from having the family doctor request a DNA genomics test along with regular blood test on a patient to determine if there is a risk of disease? It's a great question. That's where the world is going. That's the future of medicine. That's what we call personalized precision medicine. Again, it is a no-brainer that this is where medicine is going.

Ted Karkus: It's a great question. That's where the world is going. That's the future of medicine. That's what we call personalized precision medicine. Again, it is a no brainer that this is where medicine is going. I mean, just think about learning about your genetic makeup to tell you about the diseases that you're at high risk of. You need to know that so then you can prevent yourself from getting those diseases.

Speaker Change #113: It's a great question. That's where the world is going. That's the future of medicine. That's what we call personalized precision medicine.

Speaker Change #113: Again, it is a no-brainer.

Speaker Change #113: that this is where medicine is going? I mean just think about it. Learning about your genetic makeup.

Ted Karkus: You can't do that without the genetic test. And so George Church, you know, he was, you know, years ahead of his time. [inaudible] You know, decades ahead of his time. He knows this is where we're going. He believes that one day, everybody is going to be tested. He thinks babies are gonna be tested too. In fact, another initiative we're looking at is not only babies being tested, but couples before they get married and have children getting tested, if both, you know, and a couple, if they both have the same genetic mutation, that is going to cause a baby, you know, to come out with, God forbid, maybe they don't get married, maybe they don't have children, maybe they adopt or whatever.

Ted Karkus: I mean, just think about learning about your genetic genetic makeup, to tell you about disease that you're high risk of. You need to know that so then you can prevent yourself from getting those diseases. You can't do that without the genetic test. And so George Church, you know, he's, you know, years ahead of his time, you know, decades ahead of his time. He knows this is where we're going. He believes the one day everybody is going to be tested.

George Church: to tell you about diseases that you're high risk of. You need to know that, so then you can prevent yourself from getting those diseases. You can't do that without the genetic test. And so George Church, he was years ahead of his time.

Ted Karkus: You can't do that without the genetic test. And so George Church, you know, he's, you know, years ahead of his time, you know, decades ahead of his time. He knows this is where we're going. He believes the one day everybody is going to be tested. He thinks babies are going to be tested. In fact, another initiative we're looking at is not only babies being tested, but couples. Before they get married and have babies, getting tested and both, you know, in a couple of things, both have the same, you know, genetic mutation that is going to cause a baby, you know, to come out with, you know, God forbid.

George Church: You know decades ahead of his time. He knows this is where we're going he believes the one day Everybody is going to be tested. He thinks babies are going to be tested in fact another initiative. We're looking at

Ted Karkus: He thinks babies are going to be tested. In fact, another initiative we're looking at is not only babies being tested, but couples. Before they get married and have babies getting tested and both, you know, in a couple of things, both have the same, you know, genetic mutation that is going to cause a baby, you know, to come out with, you know, you know, God forbid. Maybe they don't get married. Maybe they don't have babies.

Ted Karkus: Maybe they adopt or whatever. So not only every person getting tested, but even couples getting tested before they consider having babies, getting tested. So, and interestingly, actually, that's another initiative that I mentioned that we're looking into. And this is their services, you know, dating services. And some of them are very expensive. You know, the cheap ones, everybody years about where, you know, whatever, you know, for kids. But then there's the real ones where people are serious about wanting to get married.

George Church: It's not only babies being tested, but couples, before they get married and have babies, getting tested. And both...

Ted Karkus: And those are very expensive. And they could throw a old, you know, sequencing test in there to all the individuals to match them up. So the people who shouldn't be matched up are matched up. It's an interesting additional feature. And we're talking about paying thousands, you know, it's not tens of thousands of dollars for these matchmaking services. These are the high end ones. So the grown a few hundred dollar test is a no brainer.

George Church: If Bob.

George Church: and a couple, if they both have the same genetic mutation that is going to cause a baby to come out with, you know.

Ted Karkus: Maybe they don't get married. Maybe they don't have babies. Maybe they adopt or whatever. So not only every person getting tested, but even couples getting tested before they consider having babies, getting tested. So, and interestingly, actually, that's another initiative that I mentioned that we're looking into. And this is their services; you know, dating services. And some of them are very expensive. You know, the cheap ones, everybody years about where, you know, whatever, you know, for kids. But then there's the real ones where people are serious about wanting to get married. And those are very expensive.

Ted Karkus: So not only every person getting tested, but even couples getting tested before they consider having children getting tested. So and interestingly, actually, that's another initiative I didn't even mention that we're looking into, and this is their services, you know, dating services, and some of them are very expensive, you know, the cheap ones that everybody hears about, where, you know, whatever, you know, for kids. But then there are the real ones where people are serious about wanting to get married.

Speaker Change #115: You know, God forbid. Maybe they don't get married. Maybe they don't have babies. Maybe they adopt or whatever. So not only every person getting tested, but even couples getting tested before they consider having babies.

Speaker Change #115: getting tested. Um, so and interestingly, actually, that's another initiative I didn't even mention that we're looking into. And, uh, this is their services, you know, dating services, and some of them are very expensive. You know, the cheap ones that everybody hears about where, you know,

Ted Karkus: And those are very expensive, so they could throw a whole genome sequencing test in there for all the individuals to match them up. So the people that shouldn't be matched up aren't matched up. It's an interesting additional feature. And we're talking about paying 1000s, you know, if not 10s of 1000s of dollars for these matchmaking services. These are the high-end ones. So throwing a few $100 tests is a no brainer.

Speaker Change #115: Whatever, the, you know, for kids. But then there's the real ones where people are serious about wanting to get married and those are very expensive and they could throw a

Ted Karkus: And they could throw an old, you know, sequencing test in there to all the individuals to match them up. So the people who shouldn't be matched up are matched up. It's an interesting additional feature. And we're talking about paying thousands; you know, it's not tens of thousands of dollars for these matchmaking services. These are the high-end ones. So the grown a few hundred dollar test is a no brainer. So there's a lot of ways that this can go. I hope that answers your question. I went on some; there's so much going on in our company.

Speaker Change #115: to all the individuals to match them up so the people that shouldn't be matched up aren't matched up.

Speaker Change #116: It's an interesting additional feature, and we're talking about paying thousands, if not tens of thousands of dollars, for these matchmaking services. These are the high-end ones, so throwing a few hundred dollar tests is a no-brainer. So there's a lot of ways that this can go. I hope that answers your question.

Ted Karkus: So there's a lot of ways that this can go. I hope that answers your question. I went on. There's so much going on in our company. You know, I like going on some of these Last question, please, Noelle.

Ted Karkus: You know, I like going on some of these answers.

Ted Karkus: So there's a lot of ways that this can go. I hope that answers your question. I went on some, there's so much going on in our company. You know, I like going on some of these answers.

Unknown Executive: Last question, please, Noel. Excellent.

Noel: There's so much going on in a company, you know, I like going on some of these answers. Last question, please, Noella.

Ted Karkus: Excellence Excellence. Your final question for today is, it looks like the second half of 2024 could bring several major milestone events. Will you be able to stay on top of all initiatives? Yeah, so the beauty of our company, Look, I am, I answer emails 24-7, I work 24-7, I live and breathe this. I don't do this for paychecks, I don't even do it for the shares of my company. This is just a part of my life. To be clear, I walk 13,000 to 13,500 steps every single day.

Unknown Executive: So your final question for today is, looks like the second half of 2024 could bring several major milestone events. Will you be able to stay on top of all initiatives? Yeah. So the beauty of our company, look, I answer email 24/7. I work 24-7. I live and breathe this. I don't do this for paychecks. I don't even do it for the shares of my company. This is just a part of my life. To be clear, I walk 13,000 to 13,500 steps every single day. The way I do it, I do business calls. If I don't have to be on a video, if I wasn't doing this on video right now, I would have headphones on.

Ted Karkus: Last question, please, Noel. Excellent.

Noel: Excellent. So your final question for today is, looks like the second half of 2024 could bring several major milestone events. Will you be able to stay on top of all initiatives?

Ted Karkus: So your final question for today is, looks like the second half of 2024 could bring several major milestone events. Will you be able to stay on top of all initiatives? Yeah. So the beauty of our company, look, I answer email 24-7. I work 24-7. I live and breathe this. I don't do this for paychecks. I don't even do it for the shares of my company. This is just a part of my life.

Speaker Change #117: Yeah, so the beauty of our company...

Speaker Change #118: Look, I answer emails 24-7, I work 24-7, I live and breathe this, I don't do this for a paycheck, I don't even do it for the shares of my company, this is just a part of my life.

Ted Karkus: The way I do it, I do business calls; if I didn't have to be on video, if I wasn't doing this on video right now, I would have headphones on, I would be walking while I'm talking. In fact, I recommend this call to everybody listening to this call: the most important thing you can do for your health. You don't have to run, and you can't tell me you don't have time because I'm as busy as anybody on this call. I put on headphones anytime I'm doing a business call. I walk while I talk so that I don't even notice that I'm walking.

Speaker Change #118: To be clear, I walk...

Ted Karkus: To be clear, I walk 13,000 to 13,500 steps every single day. The way I do it, I do business calls. If I don't have to be on a video, if I wasn't doing this on video right now, I would have headphones on. I would be walking while I'm talking. In fact, I recommend to everybody listening to the squalls. Most important thing you can do for your health. You don't have to rush and you can't tell me you don't have time because I'm as busy as anybody on the squall.

Speaker Change #118: 13,000 to 13,500 steps every single day. The way I do it, I do business calls. If I don't have to be on a video, if I wasn't doing this on video right now, I would have headphones on. I would be walking while I'm talking.

Ted Karkus: I would be walking while I'm talking. In fact, I recommend to everybody listening to the squalls. Most important thing you can do for your health. You don't have to rush, and you can't tell me you don't have time because I'm as busy as anybody on the squall. I put on any time I'm doing a business call. I put on headphones. I walk while I talk. I don't even notice that I'm walking. That's how I get my work out there. I also count calories. Why am I telling you this? I tell you this because I'm a highly motivated individual that's doing this for the success of doing it.

Speaker Change #118: In fact, I recommend to everybody listening to this call, it's the most important thing you can do for your health. You don't have to run. And you can't tell me you don't have time, because I'm as busy as anybody on this call.

Speaker Change #118: I put on, anytime I'm doing a business call, I put on headphones, I walk while I talk. I don't even notice that I'm walking, that's how I get my workouts in. I also count calories. Why am I telling you this?

Ted Karkus: I put on any time I'm doing a business call. I put on headphones. I walk while I talk. I don't even notice that I'm walking. That's how I get my work out there. I also count calories. Why am I telling you this? I tell you this because I'm a highly motivated individual that's doing this for the success of doing it. That's why I'm doing this.

Ted Karkus: That's how I get my workouts in. I also count calories. Why am I telling you this? I tell you this because I'm a highly motivated individual that's doing this for the success of doing it. That's why I'm doing this. So to keep up with all this, what's nice about our subsidiaries, they're all in various stages of development. They also don't all require my individual personal time, okay?

Speaker Change #118: I tell you this because I'm a highly motivated individual that's doing this for the success of doing it. That's why I'm doing this, okay?

Ted Karkus: That's why I'm doing this. So to keep up on what's nice about our subsidiaries, they're all in various stages of development. They also don't all require my individual personal time. I have great people running Nebula Genomics now. I'm really excited about what they're doing. As I said, social media is a young person's game. And the people we have in charge of Nebula and the consultants we're working with, you know, I don't know he wants me to say. Well, we said his name is Fred Stu Hollins Head and Jason Carcass together. I mean, I'm telling you they're going to kill it.

Speaker Change #118: So to keep up on these, what's nice about our subsidiaries, they're all in various stages of development. They also don't all require my individual personal time.

Ted Karkus: So to keep up on what's nice about our subsidiaries, they're all in various stages of development. They also don't all require my individual personal time. I have great people running Nebula genomics now. I'm really excited about what they're doing. As I said, social media is a young person's game. And the people we have in charge of Nebula and the consultants we're working with, you know, I don't know he wants me to say.

Ted Karkus: I have great people running Nebula Genomics now. I'm really excited about what they're doing. As I said, social media is a young person's game, and the people we have in charge of Nebula and the consultants we're working with. I don't know. He wants me to say his name. I've always said his name was Fred.

Speaker Change #118: Okay, I have great people running Nebula Genomics now. I'm really excited about what they're doing. As I said, social media is a young person's game and the people we have in charge of Nebula and the consultants we're working with

Speaker Change #119: You know, I don't I don't know he wants me to save me. Well, we said his name is Fred Stu Hollins head and Jason Karkus together

Ted Karkus: I mean, I'm telling you they're going to kill us. All right. And that's at Nebula Genomics. For BeSmart, I have the people in our company, Jed Lapkin, our COO. Understand the reason I met Jed was because he represented the former company that owned the BeSmart salvage deal. So he knows, and I also have Igor Bodd, our PhD, the two of them as a team with our FHC consultants. I just oversee and make sure everything's moving along. It's important. Listen, I gotta be honest.

Ted Karkus: Well, we said his name is Fred Stu Hollins head and Jason Carcass together. I mean, I'm telling you they're going to kill it. And that's at Nebula genomics. For B smart, I have the people in our company, Jed Lapkin or COL. Understand the reason I met Jed was because he represented the former company that owned the B smart as the individual cancer test. So we know that and I also have Igor Vod or PhD, the two of them as a team with our FHC consultants.

Ted Karkus: And that's at Nebula Genomics. For B Smart, I have the people in our company, Jed Lapkin or COL. Understand the reason I met Jed was because he represented the former company that owned the B Smart as the individual cancer test. So we know that, and I also have Igor Vod or PhD, the two of them as a team with our FHC consultants. I just oversee and make sure everything's moving along. It's important. Listen, I got to be honest. I feel it's important, not from an egotistical perspective, that I'd be involved because, at the end of the day, you need a relatively smart guy making sure that all of these across all of ours are dotted and that we're going in the right direction with the right strategy, and that's my job.

Speaker Change #120: I mean, I'm telling you they're going to kill it. All right, and that's at Nebula Genomics. For BeSmart, I have the people in our company, Jed Lapkin, our COO. Understand, the reason I met Jed was because he represented the former company that owned the BeSmart salvageable cancer test.

Speaker Change #120: So he knows it, and I also have Igor Vod, our Ph.D., the two of them as a team with our FHC consultants.

Speaker Change #121: I just oversee and make sure everything's moving along. It's important, listen, I got to be honest, I feel it's important not from an egotistical perspective than I'd be involved because at the end of the day, you need a relatively smart guy making sure that all cheese across all

Ted Karkus: I just oversee and make sure everything's moving along. It's important. Listen, I got to be honest, I feel it's important not from an egotistical perspective that I'd be involved because at the end of the day, you need a relatively smart guy making sure that all of these across all of ours are dotted and that we're going in the right direction with the right strategy, and that's my job. And my job is to make sure the right people are in place.

Ted Karkus: I feel it's important, not from an egotistical perspective, that I'm involved because, at the end of the day, you need a relatively smart guy making sure that all T's are crossed, all I's are dotted, and that we're going in the right direction with the right strategy. And that's my job. And my job is to make sure the right people are in place. But I'll be honest with you, the right people were not in place.

Ted Karkus: And my job is to make sure the right people are in place. I'll be honest with you. The right people were not in place. First of all, the people were founded. Nebula, we're scientifically minded types, built a great company, built a great platform way ahead of their time, did a great job of that, but they're not people whose expertise would be knowing how to sell it to the masses. And then, unfortunately, the team I had in place for the COVID testing wasn't the best team for building out our Nebula genomic systems. And so now I think we have a great team in place with Nebula.

Speaker Change #122: and that we're going in the right direction with the right strategy and that's my job. And my job is to make sure the right people are in place. I'll be honest with you, the right people were not in place. First of all, the people have founded.

Ted Karkus: First of all, the people who founded Nebula were scientifically minded types, built a great company, built a great platform, way ahead of their time, did a great job of that, but they're not people whose expertise would be knowing how to sell it to the masses. And then, unfortunately, the team I had in place for the culvert testing wasn't the best team for building out our Nebula jumps. And so now I think we have a great team in place with Nebula; we have a great team in place with BeSmart.

Ted Karkus: I'll be honest with you. The right people were not in place. First of all, the people were founded. Nebula, we're scientifically minded types, built a great company, built a great platform way ahead of their time, did a great job of that, but they're not people whose expertise would be knowing how to sell it to the masses. And then unfortunately, the team I had in place for the COVID testing wasn't the best team for building out our nebula genomic systems.

Speaker Change #121: Bye.

Speaker Change #123: Nebula were scientifically minded types, built a great company, built a great platform, way ahead of their time, did a great job of that, but they're not people whose expertise would be knowing how to sell it to the masses.

Speaker Change #123: And then, unfortunately, the team I had in place for the COVID testing wasn't the best team for building out our nebulae genomics business.

Ted Karkus: And so now I think we have a great team in place with Nebula. We have a great team in place with B-Smart. For Equivier, we have a great infrastructure. But because we did the Colties brand, we still have the manufacturers really. And of course, the manufacturers spend a lot of time there. In fact, Ted Lackin spent a lot of time there. So our team's great. Look, and I got an IT team world class.

Ted Karkus: We have a great team in place with B-Smart. For Equivier, we have a great infrastructure. But because we did the Colties brand, we still have the manufacturers, really. And of course, the manufacturers spend a lot of time there. In fact, Ted Lackin spent a lot of time there. So our team's great. Look, and I got an IT team world class. We have better IT here led by Sergio Morales, who worked in the government. It is like me saying that, but he's worked at the highest level. We have one of the best IT teams in the world.

Speaker Change #123: And so now I think we have a great team in place with Nebula, we have a great team in place with vSmart, for Equivir, we have a great infrastructure.

Ted Karkus: For Equivir, we have a great infrastructure, you know, but, you know, because we did the Colby's brand, we still have the manufacturing facility. And of course, you know, the manufacturing. I don't have to spend a lot of time there.

Speaker Change #123: But because we did the Colby's brand, we still have the manufacturing facility. And of course, the manufacturing, I didn't have to spend a lot of time there. In fact, Jed Latkin spent a lot of time there. So our team's great. Look, and I got an IT team, world-class. We have better IT here.

Ted Karkus: In fact, Jed Latkin spends a lot of time there. So our team's great. Look, and I got an IT team that is world class. We have better IT here, led by Sergio Morales. Who worked for the government? He doesn't like me saying that, but he's worked at the highest level. We have one of the best IT teams in the world. Normally, you see a team like this in a company worth 100 billion dollars. Not in a company our size, but what's nice about having such a strong IT team is there's so much that goes into nebula genomics behind the scenes, not only with the websites and all that kind of stuff, but also with all the products we are developing with our new ancestry test that's as good as the ancestry So I have got a great team. I know I went on on a lot here.

Ted Karkus: We have better IT here led by Sergio Morales, who worked in the government. It is like me saying that, but he's worked at the highest level. We have one of the best IT teams in the world. Normally, you see a team like this in a company worth $100 billion. Not in a company, our size. But what's nice about having such a strong IT team is there's so much that goes into nebula genomics in behind the scenes.

Speaker Change #123: led by Sergio Morales who worked in the government. He doesn't like me saying that but he's worked at the highest level. We have one of the best IT

Ted Karkus: Normally, you see a team like this in a company worth $100 billion. Not in a company, our size. But what's nice about having such a strong IT team is there's so much that goes into Nebula Genomics in behind the scenes. Not only with the websites and all that kind of stuff, but also with all the products we are developing with our new ancestry test. You know, this requires an intense amount of IT. So I got a great team. I know I went on a lot here, but what I'm saying is, it's not what I mean.

Speaker Change #123: Teams

Speaker Change #123: in the world. Normally, you see a team like this in a company worth 100 billion dollars, not in a company our size. But what's nice about having such a strong IT team is there's so much that goes into Nebula Genomics in behind the scenes, not only with the websites and all that kind of stuff, but also with all the products we are developing with our new Ancestry test that's as good as the Ancestry companies.

Ted Karkus: Not only with the websites and all that kind of stuff, but also with all the products we are developing with the our new ancestry test. You know, this requires an intense amount of IT. So I got a great team. I know I went on a lot here, but what I'm saying is, it's not what I mean. I just put a lot of the pieces together. And then we got great people working on these businesses. So, and we have a really good team.

Speaker Change #123: that we're going to take the Ancestry test and we're going to expand the reporting and give more reports and better reports than what the, you know, this requires an intense amount of IT. So I got a great team. I know I went on a lot here, but what I'm saying is it's not all me.

Ted Karkus: But what I'm saying is it's not only that I just put a lot of the pieces together. Then we have great people working on these businesses. So, and we have a really good team, and, finally, I mentioned that it took years, but I think we finally have a strong finance team. It's amazing. You have no idea behind the scenes running a public company. You have no idea what it takes to run a public company with a finance team on the water and have the right team in place.

Ted Karkus: I just put a lot of the pieces together. And then we got great people working on these businesses. So, and we have a really good team. And finally, I mentioned the finally; it's of yours. I think we finally have a strong finance thing. It's amazing. You have no idea behind the scenes running a public company. You have no idea what it takes to run a public company with the finance team. And have the right right team in place. I don't know if it needs to shout out more in names or not. But we have a very strong finance team led by Lance.

Speaker Change #124: I just put a lot of the pieces together, and then we got great people working on these businesses. So, and we have a really good team. And finally, I mentioned that finally, it took years. I think we finally have a strong finance team. It's amazing. You have no idea behind the scenes. Running a public company, you have no idea what it takes.

Ted Karkus: And finally, I mentioned the finally, it's of yours. I think we finally have a strong finance thing. It's amazing. You have no idea behind the scenes running a public company. You have no idea what it takes to run a public company with the finance team. And have the right right team in place. I don't know if it needs to shout out more in names or not. But we have a very strong finance team led by Lance.

Ted Karkus: I don't know if it needs to shout out more in names or not, but we have a very strong finance team led by Lance, but say so. I think that's how you pronounce his name.

Speaker Change #124: to run a public company with the finance team in the orders and have the right team in place. I don't know if I need to shout out more names or not, but we have a very strong finance team led by Lance.

Ted Karkus: But say sorry. I think that's how you pronounce the name. We argue about how to pronounce the last name. Anyway, I'm going on some tangents now that it just gave you what the others called for those of you to stay on a little more flavor. It's not on me. We have a really strong team in every department in every business. We have very strong consultants that we're working with. And in fact, by the way, I'll tell you, FHC was actually introduced to me by a multi-billionaire who has had great success in investing in the companies that FHC works.

Ted Karkus: We argue about how to pronounce his last name. Um, anyway, I'm going on some chances now that it just gave you at the end of this call a little more flavor. It's not on me. We have a really strong team in every department and in every business. We have very strong, um, consultants that we're working with. Um, and, in fact, by the way, I'll tell you, F. A. C. was actually introduced to me by a multi-billionaire who has had great success in investing in the companies that FHC works on.

Speaker Change #124: Let's say so.

Ted Karkus: But say sorry. I think that's how you pronounce the name. We argue about how to pronounce the last name. Anyway, I'm going on some tangents now that it just gave you what the others called for those of you to stay on a little more flavor. It's not on me. We have a really strong team in every department in every business. We have very strong consultants that we're working with. And in fact, by the way, I'll tell you, FHC was actually introduced to me by a multi billionaire who has had great success in investing in the companies that FHC works, on.

Speaker Change #124: I think that's how you pronounce his name. We argue about how to pronounce his last name. Anyway, I'm going on some tangents now. It just gave you, at the end of this call, for those of you who stayed on, a little more flavor. It's not all me. We have a really strong team in every department, in every business, we have very strong.

Speaker Change #124: consultants that we're working with. And in fact, by the way, I'll tell you FHC was was actually

Ted Karkus: And what he wanted to see was that FHC was going to get behind us with B-Smart, and that's given him a lot of confidence that B-Smart is now going to be a very successful cancer diagnostic test. So if that gives anybody any additional flavor on how I think and how I work.

Speaker Change #124: Introduced to me by a multi-billionaire who has had great success in investing in the companies that FHC works on.

Ted Karkus: on. And what he wanted to see was that FHC was going to get behind us with B-Smart, and that's given him a lot of confidence that B-Smart is now going to be a very successful cancer diagnostic test. So if that gives anybody any additional flavor on how I think and how I work.

Ted Karkus: So, and what he wanted to see was that FHC was going to get behind us with B-Smart, and that's given him a lot of confidence that B-Smart is now going to be a very successful cancer diagnosis. So, if that gives anybody any additional flavor of how I think and how I work. Noel, any other questions? Are we good to go? That's all the questions we have for today.

Speaker Change #125: So, and what he wanted to see was that FHC was going to get behind us with B-SMART, and that's given him a lot of confidence that B-SMART is now going to be a very successful cancer diagnostic test.

Unknown Executive: No other questions? Are we good to go? That's all the questions we have for today, so thank you very much, Ted, for your responses.

Speaker Change #124: So if that gives anybody any additional flavor on how I think and how I work.

Noella: So thank you very much, Ted, for your responses. That concludes the Q&A session, but before we go, I will turn back the floor to Ted for one final question. Thank you very much.

Speaker Change #124: Noelle, any other questions or are we good to go?

Unknown Executive: No other questions are we good to go?

Unknown Executive: That concludes the Q&A session, but before we go, I will turn back the floor to Ted for our final remarks. Sure. So look, thank you again for everybody for joining today. Thank you for those of you that are shareholders, for being loyal shareholders. I know it's frustrating. Stock prices are frustrating. Believe me, it frustrates me more than anybody. On the largest shareholder on the company, I am super enthusiastic about what we're building. So I put stock prices aside for a moment. Noella, I always enjoy having you moderate. Renmark, again, I do the virtual non-deal road shows.

Speaker Change #126: That's all the questions we have for today, so thank you very much, Ted, for your responses. That concludes the Q&A session, but before we go, I will turn back the floor to Ted for final remarks.

Unknown Executive: That's all the questions we have for today, so thank you very much, Ted, for your responses. That concludes the Q&A session, but before we go, I will turn back the floor to Ted for our final remarks. Sure. So look, thank you again for everybody for joining today. Thank you for those of you that are shareholders, for being loyal shareholders. I know it's frustrating. Stock prices are frustrating. Believe me, it frustrates me more than anybody.

Ted Karkus: So look, thank you again everybody for joining today. Thank you for those of you that are shareholders, for being loyal shareholders. I know it's frustrating. Stock prices are frustrating. Believe me, it frustrates me more than anybody.

Ted Karkus: Sure, so look, thank you again for everybody for joining today.

Ted Karkus: Thank you for for those of you that are shareholders for being loyal shareholders. I know it's frustrating. Stock prices are frustrating. Believe me, it frustrates me more than anybody. I'm the largest shareholder in the company. I am super enthusiastic about what we're building. So I put, I put.

Ted Karkus: I'm the largest shareholder in the company, and I am super enthusiastic about what we're building. So I put stock prices aside for a moment, Noella, I always enjoy having you moderate. Renmark, again. I do the virtual non-deal roadshows at least once a month with Renmark, so sign up with them if you want our next update. Again, we have this phenomenal relationship with Think Equity. Thank you, Hunter Diamond, for calling in. He also covers us on a research basis and does a phenomenal job.

Unknown Executive: On the largest shareholder on the company, I am super enthusiastic about what we're building. So I put stock prices aside for a moment. Noella, I always enjoy having you moderate. Renmark, again, I do the virtual non-deal road shows. At least once a month with Renmark, so sign up for them if you want our next update. Again, we have this phenomenal relationship with Think Equity. Thank you, Hunter Diamond, for calling in. He also covers us besides Think Equity.

Noel Lass: Stock prices aside for a moment. Noella, I always enjoy having you moderate. Renmark, again, I do the virtual non-deal roadshows at least once a month with Renmark, so sign up with them if you want our next update.

Unknown Executive: At least once a month with Renmark, so sign up for them if you want our next update. Again, we have this phenomenal relationship with Think Equity. Thank you, Hunter Diamond, for calling in. He also covers us besides Think Equity. He also covers us on a research basis and does a phenomenal job. And with that, I say thank you. I'm looking forward to some really positive updates as we move forward throughout the year. And I think we're going to be a very different company in the next two different future, and I'm looking forward to it. Have a great day, everyone.

Speaker Change #128: Again, we have this phenomenal relationship with Think Equity. Thank you, Hunter Diamond for calling in. He also covers us besides Think Equity. He also covers us on a research basis and does a phenomenal job and...

Ted Karkus: With that, I say thank you. I'm looking forward to some really positive updates as we move forward throughout the year. I think we're gonna be a very different company in the not too distant future, and I'm looking forward to it. Have a great day, everyone! Thank you again, and thank you, Noella. Thank you very much, Ted, for your presentation, and thank you everyone for joining us today for the Prophase Lab 2nd Corps of 2024 results.

Unknown Executive: He also covers us on a research basis and does a phenomenal job. And with that, I say, thank you. I'm looking forward to some really positive updates as we move forward throughout the year. And I think we're going to be a very different company in the next two different future, and I'm looking forward to it. Have a great day, everyone. Thank you again, and thank you, Noella. Thank you very much, Ted, for your presentation. And thank you, everyone, for joining us today for the Profase Labs 2nd Corps of 2024 results. Profase is trading on the NASDAQ under the ticker symbol PRPH.

Speaker Change #129: With that, I say, thank you. I'm looking forward to some really positive updates as we move forward throughout the year. And I...

Unknown Executive: Thank you again, and thank you, Noella. Thank you very much, Ted, for your presentation. And thank you, everyone, for joining us today for the Profase Labs 2nd Corps of 2024 results. Profase is trading on the NASDAQ under the ticker symbol PRPH. The playback will be available on our website 24 to 48 hours after this presentation under the V&D or LARP tab. Please stay tuned for the next quarterly call, and see you next time.

Ted Karkus: Prophase is trading on the NASDAQ under the ticker symbol PRPA. The playback will be available on our website 24 to 48 hours after this presentation under the V&ER Library tab. Please stay tuned for the next quarterly call and see you next time.

Speaker Change #129: Thank you very much, Ted, for your presentation and thank you everyone for joining us today for the Prophase Lab's second quarter of 2024 results.

Speaker Change #130: Prophase is trading on the NASDAQ under the ticker symbol PRPH. The playback will be available on our website 24 to 48 hours after this presentation under the V&DR Library tab. Please stay tuned for the next quarterly call and see you next time.

Unknown Executive: The playback will be available on our website 24 to 48 hours after this presentation under the V&D or LARP tab.

Unknown Executive: Please stay tuned for the next quarterly call and see you next time.

Speaker Change #130: you you